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ABSTRACT
The urinary bladder relies on complex and interconnected neural circuits in the
peripheral and central nervous systems to properly coordinate micturition. Local sensory
signals in the bladder produce neurochemical changes that are relayed and integrated to
allow a switch from the storage phase to the elimination phase of the micturition reflex .
These local signals can result from mechanical distension that occurs during bladder filling
or can be the result of maladaptive neurotransmission due to noxious stimuli and/or
inflammation. The latter occurs frequently in individuals with a chronic pain pathology
called interstitial cystitis (IC)/bladder pain syndrome (BPS). Patients with IC/BPS typically
present with persistent pelvic pain and severe urinary frequency/urgency that cannot be
explained by identifiable causes (e.g.: bacterial, viral, fungal). Though the etiology is
unknown, IC/BPS patient symptoms are associated with the breakdown of the uroepithelial
barrier and neurogenic inflammation that results in the sensitization of peripheral and
central nervous system circuits. In this dissertation, we identify two distinct neurochemical
mediators that we have found are important for urinary bladder function and dysfunction
using cyclophosphamide (CYP)-induced cystitis, a bladder-centric, chemically inducible,
animal model for IC/BPS.
The first aim examines vascular endothelial growth factor (VEGF) signaling with
its main receptor, VEGF receptor 2 (VEGFR2). High expression of VEGF in the bladder
has previously been implicated in increased afferent nerve sensitization and pelvic pain in
rodents and humans. Using open-outlet conscious cystometry to measure voiding function,
we found changes in bladder function outcomes after blocking VEGF/VEGFR2 signaling
using a potent VEGFR2 antagonist in naïve rats and rats treated with acute and chronic
CYP. To further elucidate the contribution of VEGF signaling in bladder inflammation, we
used RT-qPCR to quantify the presence of VEGF alternative splice variant gene expression
in different layers of the urinary bladder (urothelium and detrusor) and the lumbosacral
dorsal root ganglia, and spinal cord. We observed changes in VEGF isoform gene
expression in these tissues dependent on the duration of CYP-treatment (acute vs. chronic).
The second aim examines the role of mechanotransduction in urinary bladder
function and dysfunction, with a particular emphasis on Piezo1, a non-selective calcium
(Ca2+) permeable ion channel. Using a non-invasive, natural voiding assay, we established
a role for Piezo1 activation in increased bladder voiding frequency in naïve (no CYP) rats.
On a molecular level, we used RT-qPCR to quantify the gene expression of several
mechanosensitive channels and found consistent upregulation in the bladder after chronic
CYP-induced cystitis. In addition, we measured urothelial Ca2+ activity following Piezo1
activation and found a CYP-dependent increase in Ca2+ network activity. Lastly, we
assessed changes in tight junction gene expression following in vivo Piezo1 activation and
found that several urothelial tight junction genes are downregulated.
These results underscore the multifaceted signaling within the urinary bladder in
normal, and especially in pathological, conditions. Using a multidisciplinary approach, we
identified two mediators that contribute to voiding function and dysfunction. Future
treatments for IC/BPS will certainly be individualized and will not be a one size fits all
approach. Therefore, research into the numerous neurochemical mediators that contribute
to IC/BPS is paramount to understanding and treating the functional bladder impairments
experienced by patients.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW
1.1. The Lower Urinary Tract
1.1.1. Anatomy
Proper micturition relies on the components of the Lower Urinary Tract (LUT; the
bladder and urethra), working together in a reciprocal manner to store and eliminate urine.
In the storage phase, the bladder remains relaxed to act as a reservoir to collect urine
produced by the kidneys, while the urethra stays contracted to prevent leakage. During
elimination, the bladder contracts, and acts as a pump to expel urine through the relaxed
urethra. To achieve this dual function, the macro- and microstructure of the urinary bladder
reflect these opposing functions required for proper micturition (Tank and Grant 2012).
Externally, the apex of the bladder is the most superior, and is attached to the
umbilicus by the median umbilical ligament, a developmental remnant of the urachus
(Tank and Grant 2012). The base, or fundus, of the bladder is located most posteriorly and
demarcates the inner trigone (Andersson 2004, Tank and Grant 2012). The body is the main
part of the bladder and is located between the apex and the base (Tank and Grant 2012).
Lastly, the bladder neck is located most inferiorly and is continuous with the urethra (Tank
and Grant 2012).
Like the bladder, the structure of the urethra also mirrors its opposing functions; its
overarching role being a conduit to transport urine from the bladder to the outside of the
body via the external urethral orifice (i.e.: the urinary meatus; Pradidarcheep, Wallner et
al. 2011, Tank and Grant 2012). The urethra is continuous with the bladder neck via a
circular ring of smooth muscle called the internal urethral sphincter and is externally
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surrounded by striated muscle from the pelvic floor (Pradidarcheep, Wallner et al. 2011).
This muscular division of the pelvic floor around the urethra is called the external urethral
sphincter and is a necessary component of continence and the voluntary aspect of
micturition (Pradidarcheep, Wallner et al. 2011). In males, the urethra is about 20
centimeters (cm) long and is divided into three parts named for their location: 1) the
prostatic urethra (the uppermost segment located within the prostate), 2) the membranous
urethra (the shortest segment and the one that passes through the external urethral
sphincter), and 3) the spongy (penile) urethra, which is the longest segment (Tank and
Grant 2012). In females, the urethra is about 5 cm long and is embedded within the vaginal
wall extending from the internal urethral orifice in the urinary bladder to the external
urethral orifice in the vestibule of the vagina (Tank and Grant 2012).
Internally within the urinary bladder, the trigone is a triangular region located
within the region of the base of the bladder and is delineated by two ureteric orifices and
the internal opening of the urethra (Tank and Grant 2012). Within the bladder wall, there
are several internal layers including: 1) the mucosa (innermost portion), 2) the muscularis
propria, which includes the detrusor smooth muscle layer, and 3) the adventitia/serosa. The
innermost layer (the mucosa) that lines the lumen, is further divided into a basement
membrane, the uroepithelium (i.e.: urothelium), and the lamina propria.
The urothelium is a specialized layer of epithelial cells that lines the inner surface
of the renal pelvis, the ureters, and the urinary bladder. The urothelium itself is also divided
into layers: a basal cell layer connected to a basement membrane, an intermediate layer,
and an apical layer made of hexagonal cells called “umbrella cells” (Khandelwal, Abraham
et al. 2009, Birder and Andersson 2013). Tight junction proteins exist between the
2

superficial umbrella cells to maintain a barrier between urine and the inner layers of the
bladder wall (Birder and Andersson 2013). Specifically, claudin-2, -4, -8, -12, zonula
occludens-1, and occludin are expressed throughout the bladder wall. Claudin-4, -8, and 12 have been localized to the umbrella cells in the urothelium suggesting a prominent role
in barrier function and maintaining transepithelial resistance (Lavelle, Meyers et al. 2000,
Acharya, Beckel et al. 2004, Rickard, Dorokhov et al. 2008). In addition, umbrella cells
themselves are covered with a layer of glycosaminoglycans, which further contribute to the
role of the urothelium as a functional barrier (Birder and Andersson 2013). Along with this
barrier function, there is strong evidence that the urothelium can relay signals regarding
bladder fullness and nociception via stretch receptors and neuromodulators to deeper layers
of the bladder wall and ultimately, to the central nervous system (CNS).
The lamina propria is another functionally important component of the bladder
mucosa. It lies between the muscularis propria and the basement membrane of the
urothelium and contains several important cell types including, fibroblasts, adipocytes,
interstitial cells, and both afferent and efferent nerve endings (Andersson and McCloskey
2014). Like the urothelium, research suggests that the lamina propria plays a similar role
in signal transduction of mechanosensation and nociception, in addition to promoting
bladder compliance and producing growth factors to signal to the overlying urothelium and
underlying detrusor muscle (Andersson and McCloskey 2014).
1.1.2. Neural Control of Micturition
Neural circuits in the brain and spinal cord are necessary to coordinate the actions
of the bladder and urethra to switch between the storage phase and the elimination phase
(Fig. 1-1). This coordination is mediated by three sets of peripheral nerves: 1) Hypogastric
3

sympathetic nerves that inhibit the detrusor muscle and contract the bladder base and
urethra for proper storage, 2) Pelvic parasympathetic nerves that contract the detrusor
muscle and relax the urethra for voiding, and 3) Pudendal somatic nerves that excite the
striated external urethral sphincter to close the bladder outlet (Yoshimura and Chancellor
2003). All three peripheral nerves also contain afferent nerves that convey sensory
information related to bladder filling (Walsh 1986, Andersson and Michel 2011). Finally,
higher order brain areas provide input to the micturition circuit to promote voluntary
control of voiding.
Bladder storage, and therefore continence, is in part maintained by the sympathetic
nervous system. Sympathetic preganglionic neurons that innervate the bladder originate in
the intermediolateral nucleus of spinal cord levels T11-L2 in humans and L1-L2 in rodents
(Nadelhaft, Vera et al. 1992). After leaving the spinal cord, these sympathetic fibers form
lumbar splanchnic nerves. Most fibers within the lumbar splanchnic nerves form synapses
on neurons in the inferior mesenteric ganglion. After synapsing, postganglionic
sympathetic fibers form the hypogastric nerve and travel towards the bladder where they
release norepinephrine to provide inhibitory input to the detrusor to promote bladder
accommodation via β-adrenergic receptors, and excitatory input to the bladder base and
smooth muscle of the urethra to facilitate storage via α-adrenergic receptors (Andersson
and Arner 2004, Fowler, Griffiths et al. 2008, de Groat, Griffiths et al. 2015).
Parasympathetic preganglionic neurons that innervate the bladder and urethra are
in the sacral parasympathetic nucleus in the lateral horn of the sacral spinal cord (S2-S4 in
humans, L6-S1 in rodents; Walsh 1986). Axons from these neurons leave the spinal cord
and immediately separate to become pelvic splanchnic nerves (i.e.: the pelvic nerve).
4

Axons within this nerve either synapse onto postganglionic neurons in the pelvic plexus or
onto postganglionic neurons located in terminal ganglia within the bladder wall (e.g.,
intramural ganglia or major pelvic ganglia; DeGroat and Saum 1976, de Groat 1990,
Elbadawi 1996, Fowler, Griffiths et al. 2008, de Groat, Griffiths et al. 2015). Throughout
bladder filling, the parasympathetic nervous system is inhibited, however, when the time
comes to initiate voiding, the parasympathetic nervous system is activated alone and leads
to the contraction of the detrusor smooth muscle through the release of acetylcholine and
ATP onto muscarinic (M3) and purinergic (P2X) receptors, respectively. Additionally,
parasympathetic fibers from the pelvic nerve relax the internal urethral sphincter through
the release of nitric oxide (Bennett, Kruse et al. 1995).
The external urethral sphincter is striated muscle and is therefore controlled by the
somatic nervous system. Motor neurons responsible for innervating the external urethral
sphincter reside in Onuf’s nucleus (humans) or the dorsolateral motor nucleus (rodents),
both of which are a collection of motor neurons in the ventral horn of the upper sacral
spinal cord. These neurons send projections to contract the external urethral sphincter via
the pudendal nerve to maintain continence in synchronized fashion with the sympathetic
nervous system (de Groat 1990, Elbadawi 1996, Fowler, Griffiths et al. 2008).
Afferent nerves containing sensory information related to bladder fullness travel to
the spinal cord via the pelvic and hypogastric nerves, whereas sensory input from the
bladder base and urethra travel to the spinal cord via the pudendal and hypogastric nerves
(Fowler, Griffiths et al. 2008). During normal bladder filling, sensory information travels
via myelinated Aδ-fibers that respond to mechanosensory channels that become activated
during passive distension of the bladder. As the bladder nears capacity, tension increases
5

and mechanosensitive channels that respond to pressure open to promote signaling that
leads to increased firing of these Aδ-fibers (Fowler, Griffiths et al. 2008). Under
pathological conditions, small diameter, unmyelinated, C-fibers are recruited to carry
sensory signals related to noxious stimuli from the LUT to the spinal cord. The cell bodies
of both Aδ- and C-fibers are in dorsal root ganglia (DRG) in spinal levels T11-L2 and S2S4 in humans (Fowler, Griffiths et al. 2008, de Groat and Yoshimura 2010). Bladder
afferents enter the spinal cord through Lissauer’s tract and terminate on neurons in the
superficial dorsal horn, dorsal commissure, and sacral parasympathetic nucleus. Some
neurons then project rostrally to supraspinal micturition integration centers in the brain.
Supraspinal neural substrates play a fundamental role in the initiation of voiding as
well as maintaining continence. In humans, the pontine micturition center (PMC), also
called Barrington’s nucleus, is located in the pontine medial tegmentum within the
brainstem and is the most prominent efferent nucleus within the micturition reflex circuit
(de Groat 1990, Elbadawi 1996, Fowler, Griffiths et al. 2008, Andersson and Michel 2011,
de Groat, Griffiths et al. 2015). Chemical or electrical activation of the PMC causes a
contraction of the detrusor smooth muscle and a relaxation of the urethra that results in
micturition (Sugaya, Matsuyama et al. 1987, Hou, Hyun et al. 2016). To accomplish this,
the PMC sends descending fibers to the sacral parasympathetic nucleus in the spinal cord
to synapse on parasympathetic neurons, to induce detrusor contraction, as well as
GABAergic interneurons that inhibit alpha motor neurons in Onuf’s nucleus to promote
relaxation of the external urethral sphincter (Andersson and Michel 2011). Though the
PMC is considered the micturition control center, in that it switches the LUT from a state
of storage to a state of elimination, it does not directly receive afferent input from the LUT
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in humans (Andersson and Michel 2011). Instead, a separate brain area is responsible for
receiving afferent input from the urinary bladder. Specifically, after Aδ- and C-fibers
synapse in the spinal cord, their projections join ascending spinal projections to synapse in
the periaqueductal gray (PAG), a region in the mesencephalon of the brainstem (Andersson
and Michel 2011). The PAG is strongly connected to the PMC and serves as an integration
center of LUT sensory signals along with inputs from other higher order brain regions such
as the hypothalamus, preoptic region, central nucleus of the amygdala, BNST, and
prefrontal cortex (Beckel and Holstege 2011). During bladder filling, input from these
brain areas prevent the PAG from exciting neurons in the PMC to maintain conscious and
voluntary control of micturition (Fowler, Griffiths et al. 2008, Beckel and Holstege 2011).
In other words, the PMC is the switch controlling the micturition reflex and the PAG is the
operator deciding when it is time to flip the switch (Andersson and Michel 2011).
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Figure 1-1: Neural control of micturition. Different components of the peripheral nervous
system (PNS) are responsible for the dual functions of the urinary bladder (i.e.: storage vs.
elimination). The hypogastric nerve contains sympathetic post ganglionic axons that originate
in the lumbosacral spinal cord (levels T11-L2 in humans). These axons maintain bladder storage
by inhibiting detrusor contractions and exciting urethral smooth muscle. The pelvic nerve
contains parasympathetic axons that originate in in the sacral spinal cord (S2-S4 in humans).
These axons eventually reach the bladder and promote detrusor contraction which results in
elimination of bladder contents. Lastly, the pudendal nerve contains somatic axons of motor
neurons located in Onuf’s nucleus in S2-S4 of the spinal cord in humans. These axons excite
the striated muscle of the external urethral sphincter to maintain continence.

1.1.3. Neurochemistry of LUT Afferent Neurons
Afferent fibers traveling in the pelvic, hypogastric, and pudendal nerves
continuously convey information from the LUT to the sacral spinal cord. The sensations
relayed by the afferent nerves to the CNS are diverse and can range from the degree of
bladder distension to sensations of pelvic pain. To produce such diverse sensations, there
are a variety of activation stimuli for afferent nerves within the LUT and the Aδ- and Cfibers each exhibit diverse properties (Andersson and Michel 2011).
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Aδ afferent fibers are mainly stimulated by mechano-induced activation during
bladder distension. These fibers are silent when the bladder is empty, however, as the
bladder begins to fill, these fibers produce a graded increase in discharge frequency at
intravesical pressures that are above a certain, individualized, pressure threshold (Janig and
Morrison 1986, Bruns, Gaunt et al. 2011). Electrophysiological studies in cats and rats have
revealed that the normal micturition reflex is triggered by myelinated Aδ-fiber afferents.
In contrast to the low threshold, mechanosensitive Aδ-bladder afferents, C-fiber afferents
are generally mechano-insensitive (Habler, Janig et al. 1990). Instead, C-fibers are
nociceptive and respond to cold stimuli or chemical/noxious stimuli like high potassium,
low pH, high osmolality, and irritants such as capsaicin (McMahon and Abel 1987, Fall,
Lindstrom et al. 1990, Habler, Janig et al. 1990, Maggi 1996). Following exposure to
noxious substances, C-fibers transition to become mechanosensitive, and their sensitivity
to bladder distension increases accordingly (de Groat, Griffiths et al. 2015).
Immunohistochemistry studies have shown that LUT afferent neurons express
various neuropeptides including substance P (SP), calcitonin gene-related peptide (CGRP),
pituitary adenylate cyclase-activating peptide (PACAP), leucine enkephalin, corticotropin
releasing factor (CRF), and vasoactive intestinal polypeptide (VIP; De Groat 1986, Vaillant
1987, Keast and De Groat 1992, Vizzard 2001, Vizzard 2006, de Groat, Griffiths et al.
2015). These modulators have been identified in several species along sensory neurons,
including: 1) neuronal cell bodies in the lumbosacral DRG, 2) axon terminals in the bladder
and urethra, specifically in the lamina propria, and 3) axon terminals in the lumbosacral
spinal cord, mainly concentrated in Lissauer’s tract in lamina I, along the lateral edge of
the dorsal horn, and in the region of the parasympathetic nucleus (Kawatani, Erdman et al.
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1985, Kawatani, Nagel et al. 1986, Kawatani, Suzuki et al. 1996, Morrison, Carter et al.
2001, Vizzard 2001, de Groat, Griffiths et al. 2015).
Bladder afferents also express various receptors, including: transient receptor
potential vanilloid 1 (TRPV1; the capsaicin receptor), transient receptor potential vanilloid
4 (TRPV4), transient receptor potential ankyrin 1 (TRPA1; activated by cold),
tropomyosin-related kinase A (TrkA) which is activated by nerve growth factor (NGF),
tropomyosin-related kinase B (TrkB) which is activated by brain-derived neurotrophic
factor (BDNF), muscarinic receptors (M2, M3, and M4), adrenergic receptors (both α and
β), Neurokinin (NK) receptors activated by tachykinin and SP, endothelin receptors, and
purinergic receptors (P2X2, P2X3 P2Y) activated by ATP (Bennett, Dmietrieva et al. 1996,
Lecci, Tramontana et al. 1998, Laird, Olivar et al. 2000, Kamo, Chancellor et al. 2005,
Kobayashi, Fukuoka et al. 2005, Everaerts, Gevaert et al. 2008, Streng, Axelsson et al.
2008, Nandigama, Bonitz et al. 2010, Michel 2015). Like the neuropeptides, these
receptors have been detected in axons within the bladder as well as along the afferent
projections in the lumbosacral spinal cord. Repeated activation of many of these receptors
induces neuroplasticity, enhances afferent nerve activity, and stimulates the release of
neurotransmitters leading to reflexive bladder activity. Though activation of the
aforementioned receptors plays a large role in bladder afferent nerve activity, the chemical
modulation of these neurons is complex, and non-neuronal cells, such as urothelial cells,
also play a role through the release of chemical messengers that interact with these afferent
neurons.
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1.1.4 Urothelial Signaling
Afferent nerves are not the only signaling cells within the LUT. Though historically
thought of as solely a passive barrier, research now suggests an integral role of the
urothelial layer of the LUT as a sensory and signaling organ that receives, amplifies, and
transmits both mechanical and chemical signals to cells deeper in the bladder wall. As
evidence of this, a variety of receptors found on afferent neurons in the bladder are also
found on urothelial cells, including: bradykinin receptors (Chopra, Barrick et al. 2005),
neurotrophin receptors (TrkA, TrkB, and p75; Murray, Malley et al. 2004), purinergic
receptors (P2X and P2Y; Lee, Bardini et al. 2000, Birder, Ruan et al. 2004, Tempest, Dixon
et al. 2004, Chopra, Gever et al. 2008), vascular endothelial growth factor (VEGF)
receptors (Saban, Backer et al. 2008, Kopparapu, Boorjian et al. 2013), adrenergic
receptors (both α and β; Birder, Apodaca et al. 1998, Birder, Nealen et al. 2002, Limberg,
Andersson et al. 2010, Kullmann, Downs et al. 2011), muscarinic and nicotinic
acetylcholine receptors (Birder, Apodaca et al. 1998, Beckel, Kanai et al. 2006, Kullmann,
Artim et al. 2008, Kullmann, Artim et al. 2008, Beckel and Birder 2012), sodium channels
(Smith, Mackler et al. 1998, Wang, Lee et al. 2003, Araki, Du et al. 2004), a variety of
TRP channels (TRPV1, TRPV2, TRPV4, TRPM8, and TRPA1; Birder, Kanai et al. 2001,
Birder, Nakamura et al. 2002, Stein, Santos et al. 2004, Gevaert, Vriens et al. 2007, Du,
Araki et al. 2008, Kullmann, Shah et al. 2009, Mochizuki, Sokabe et al. 2009, Yamada,
Ugawa et al. 2009, Girard, Campbell et al. 2019), and Piezo1/2 (Liu, Sun et al. 2018,
Dalghi, Clayton et al. 2019, Marshall, Saade et al. 2020)
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Activation of these channels and receptors occurs due to various stimuli such as
increases in bladder wall tension from bladder filling, soluble chemical mediators in urine,
and chemical mediators released from afferent neurons, inflammatory cells, and blood
vessels (LaBerge, Malley et al. 2006, Birder and de Groat 2007, Hanna-Mitchell, Beckel
et al. 2007, Birder and Andersson 2013). In response to activation of these channels,
urothelial cells release an array of signaling molecules including NO, ATP, NGF, and SP
onto both afferent and efferent nerves located in or near the urothelial cell layer (Ferguson,
Kennedy et al. 1997, Birder, Apodaca et al. 1998, Burnstock 2001, Birder, Barrick et al.
2003, Birder and Andersson 2013, Girard, Campbell et al. 2019).
ATP is one of the main urothelial signaling mediators and its release from urothelial
cells and subsequent binding to P2X receptors on afferent nerve terminals is essential for a
proper functioning micturition reflex. As the bladder fills, the apical surface of the
urothelial cells begins to stretch, which leads to activation of stretch activated channels
(SACs). This activation leads to an influx of calcium (Ca2+) and ultimately results in a
robust release of ATP from the urothelial cells (Ferguson, Kennedy et al. 1997). The
precise mechanism of this release is still debated and is certainly not limited to a singular
mechanism (Birder and Andersson 2013, Winder, Tobin et al. 2014). Indeed, most research
supports a combination of both ATP release via vesicular exocytosis and non-vesicular
release through channels like pannexin and connexin, among other transporters
(Lazarowski 2012, Sui, Fry et al. 2014, Winder, Tobin et al. 2014). For vesicular release,
ATP is typically co-packaged into vesicles and released with other neurotransmitters like
acetylcholine (Unsworth and Johnson 1990, Dahl 2015). For non-vesicular release in
urothelial cells, ATP can leave the cell through non-junctional connexin or pannexin
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hemichannels and signal through both autocrine and paracrine mechanisms (Beckel,
Daugherty et al. 2015).
In the urinary bladder, connexin-43 is the most widely studied connexin channel
and as such, has been implicated in numerous bladder pathologies including bladder outlet
obstruction (Haefliger, Tissières et al. 2002), bladder overactivity (Christ, Day et al. 2003),
and neurogenic detrusor (Haferkamp, Mundhenk et al. 2004). Unlike many other gap
junctions formed by connexins, connexin-43 can be located at the surface of the cell,
connecting the cytosolic space to the extracellular space, thereby providing a conduit to
transport ATP out of the cell (Sengiku, Ueda et al. 2018, Kono, Ueda et al. 2021). Recently,
connexin-43 expression has been localized specifically at the level of the mouse urothelium
(in addition to the known expression of connexin-43 in detrusor smooth muscle cells), and
a specific knockout of urothelial connexin-43 results in decreased luminal ATP release
compared to wildtype mice (Kono, Ueda et al. 2021).
There are three pannexin channels in vertebrates (pannexin-1, -2, and -3), but
notably, the bladder has one of the highest levels of pannexin-1 gene expression in the
entire body (Hanstein, Negoro et al. 2013). Pannexin-1 is mechanosensitive and is activated
by increased intracellular Ca2+ (Bao, Locovei et al. 2004, Dahl 2015, Sana-Ur-Rehman,
Markus et al. 2017). In response, pannexin-1 transports ATP from the cytosol to the
extracellular space (Locovei, Wang et al. 2006). Given the robust singling capabilities of
the urothelium, mainly due to the release of ATP, the varied mechanisms of ATP release
yield several potential new targets for the treatment of pathologies related to bladder
signaling dysfunction.
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1.2. Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
1.2.1. History of the Pathology
In the early 19th century, the first interstitial cystitis (IC)-like condition was
diagnosed by Dr. Philip Syng Physick, a renowned surgeon from Philadelphia (Meijlink
2014). In his diagnosis, he described inflammation of the bladder as an “ulcer”, presenting
similar symptoms to that of a bladder stone. He then expanded on this definition to include
symptoms like chronic voiding frequency, urgency, and pain, in the absence of
“demonstrable etiology” (Meijlink 2014). Though Physick never recorded anything in
writing, the culmination of the ulcer symptoms he described were collectively known as
“tic douloureux of the bladder” (Meijlink 2014). The term “interstitial cystitis” itself first
appeared in 1876 and was used to describe the degree of intensity of the inflammation,
such that if the submucosal and intermuscular tissues become involved, the diagnosis
would be “interstitial cystitis” whereas if the inflammation extended to the serous layer of
the bladder, the diagnosis would be “epi-cystitis” (Skene 1878).
Over the next century, several doctors studied this pathology, however, progress
was slow due to internal debates in the field over nomenclature (e.g.: what is meant by the
term “ulcer”?) as well as pathological diagnostic criteria. For example, Dr. Guy Hunner,
an obstetrician and gynecologist at Johns Hopkins Hospital, used a cystoscope to
characterize the “ulcers” and his descriptions were the gold standard in the field for several
years. Because of this, the trademark symptom, and the pathology itself, became known as
“Hunner(‘s) Ulcers” (Meijlink 2014). This raised flags for physicians in the field for
several reasons. First, physicians noted that since the diagnosis included the word “ulcer”,
it was inherently misleading and because of that, they worried that less experienced
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physicians would expect to see a true ulcer at cystoscopy and when they failed, they would
not diagnose genuine cases (Meijlink 2014). Second, in 1987, Fall, et al. described IC as a
heterogenous disorder and noted several clinical differences between ulcerative (classic)
IC and non-ulcerative IC (Fall, Johansson et al. 1987).
Debates on IC terminology and inclusion criteria are ongoing, spurring the creation
of several research symposiums and study networks, like the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) Multidisciplinary Approach to the Study of
Chronic Pelvic Pain Network (MAPP) which was created in 2008 (Meijlink 2014). Since
then, several entities around the world have created their own name, definition of the
pathology, and inclusion criteria. In the US, one of the most widely used definitions was
made by the American Urological Association (AUA) in 2011. They created the term
“Interstitial Cystitis/Bladder Pain Syndrome” (IC/BPS) and define it as: “An unpleasant
sensation (pain, pressure, discomfort) associated with lower urinary tract symptoms (eg:
frequency, urgency, and/or nocturia) of more than 6 weeks duration, in the absence of
infection or other identifiable causes” (Meijlink 2014). The definition was purposefully
kept broad and short to increase the possibility of early detection and treatment (McLennan
2014). Notably, the AUA definition does not specify the presence of glomerulations (i.e.:
Hunner’s ulcers) as inclusion criteria like other entities’ (eg: NIDDK) definitions. The
AUA stated that this was intentional and is a result of a lack of knowledge of mechanism
and clinical significance of the glomerulations, since it is estimated that 60% of people who
present with IC/BPS do not have glomerulations (Meijlink 2014).
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1.2.2. Prevalence and Economic Burden
Getting accurate epidemiological statistics on IC/BPS is challenging due to the lack
of a universally accepted name, inconsistent clinical features, and varying timeframe used
to diagnose the pathology. According to the RAND Interstitial Cystitis Epidemiology
(RICE) Study, by using a telephone survey given to American households, they identified
that 2.7-6.5% of women and 1.9-4.2% of men meet the IC/BPS diagnostic criteria (Berry,
Elliott et al. 2011, Suskind, Berry et al. 2013). That amounts to about 3.5-8.6 million
women and 2.4-5.3 million men (Berry, Elliott et al. 2011, Suskind, Berry et al. 2013).
These data suggest that the number of male cases approach that of female cases, however,
other studies have found that cases in women outweigh cases in men 5:1 (Berry, Elliott et
al. 2011), while others suggest as many as 90% of cases of IC/BPS are found in women
(Cox, Golda et al. 2016). This may indicate that IC/BPS may be underreported as well as
underdiagnosed in men.
IC/BPS represents a significant economic burden in the United States since,
according to a separate RICE study, 42% of women with IC/BPS stated that they were
unemployed and 11% stated that their unemployment was a direct result of their IC/BPS
symptoms (Bogart, Suttorp et al. 2012, Beckett, Elliott et al. 2014). As a result of this lost
income as well as the medical costs in general, the economic burden in the US is over $400
million per year (Anger, Zabihi et al. 2011).
1.2.3. Pathophysiology of IC/BPS
An understanding of the pathology of IC/BPS and specifically the mechanisms that
underlie the symptoms of the disorder, is crucial for finding a successful treatment. Though
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the etiology is still unknown, research has suggested several mechanisms that underlie the
urinary frequency, urgency, and pelvic pain that are commonly seen in patients with
IC/BPS.
As mentioned in previous sections, one function of the urothelial layer of the
bladder is a protective barrier that shields deeper layers of the bladder wall from toxic
metabolites found in the urine. This barrier function is strong due to the tight junction
proteins between apical urothelial cells as well as the layer of glycosaminoglycans that
cover the umbrella cells (Hurst, Greenwood-Van Meerveld et al. 2015). Clinically, many
research studies have shown a breakdown of the urothelium as well as reduced expression
of urothelial tight-junction proteins in patients with IC/BPS (Elbadawi and Light 1996,
Tomaszewski, Landis et al. 2001, Liu, Shie et al. 2012, Keay, Birder et al. 2014, Hurst,
Greenwood-Van Meerveld et al. 2015). Other research suggests that this urothelial
breakdown is secondary to localized bladder inflammation seen in patients with IC/BPS
(Grundy, Caldwell et al. 2018). Though severe inflammation is only found in patients with
Hunner’s ulcers, there is a marked increase in pro-inflammatory mediators, chemokines,
and cytokines in the bladder and/or urine of individuals diagnosed with IC/BPS (Kastrup,
Hald et al. 1983, Leiby, Landis et al. 2007, Jacobs, Smaldone et al. 2010, Jhang and Kuo
2016, Guo, Chang et al. 2018). As a result of the inflammation-induced urothelial damage,
tight-junction proteins, like claudins, are downregulated, and the permeability of the
bladder increases which allows solutes such as water, urea, ions, and other toxic
metabolites to pass into deeper layers of the bladder that contain muscle cells, nerve
endings, and blood vessels (Birder and Andersson 2013).
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When inflammation becomes chronic, neurogenic inflammation can occur.
Neurogenic inflammation (Fig. 1-2) is a component of the positive feedback loop that is
triggered when increased stimulation of afferent nerves causes them to release
inflammatory peptides including SP, CGRP, and neurokinin A (Birder and Kullmann
2018). This release of neuropeptides causes a cascade of events involving the immune
system, the vasculature, and the nervous system in the following ways: 1) the vasculature
becomes angiogenic which can increase edema thereby perpetuating the inflammatory
response (Birder and Kullmann 2018), 2) immune system activation induces recruitment
of additional pro-inflammatory mediators like mast cells and leukocytes to the site of
inflammation (Birder and Kullmann 2018), and 3) the underlying nerves become
hyperexcitable due to increased nerve density (Pang, Marchand et al. 1995), increased
expression of receptors such as TRPs, and purinergic receptors (Brady, Apostolidis et al.
2004, Brady, Apostolidis et al. 2004, Birder and Kullmann 2018), and increased activation
and expression of free ions like K+ and Ca2+ that lower the action potential threshold in
sensory neurons (de Groat and Yoshimura 2006, de Groat and Yoshimura 2010). This
persistent activation of peripheral nociceptive signals creates an increased drive of C-fiber
afferent input to the spinal cord which, over time, leads to aberrant functioning of CNS
circuits. Specifically, nociceptive neurons in the brain and spinal cord will increase their
firing given normal or sub-threshold stimuli (Baron, Hans et al. 2013). This phenomenon
is called central sensitization and is the driver of the hyperalgesia (increased sensitivity to
pain) and allodynia (increased pain response to neutral stimuli) symptoms in patients with
IC/BPS (Reynolds, Dmochowski et al. 2016).
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Figure 1-2: Mechanism of neurogenic inflammation. Increased release of neuromodulators like
Substance P (SP), nerve growth factor (NGF), adenosine triphosphate (ATP), and nitric oxide (NO) from
urothelial cells leads to increased activation of sensory nerve terminals. This increased activation leads
to the release of inflammatory peptides like SP and calcitonin gene-related peptide (CGRP) from the
terminals which perpetuates the immune response causing prolonged edema, recruitment of mast cells
that also release NGF, increased expression of free ions like K + and Ca2+ that lower the action potential
threshold, and increased nerve plasticity and branching. Continuous activation of the afferent terminals
leads to increased synthesis of receptors and ion channels like transient receptor potential cation channel
subfamily V member 1 (TRPV1), neurokinin-1 (NK-1), and purinergic receptors (P2X), in the neuronal
cell body that are then transported to the site of the injury, further contributing to aberrant C-fiber afferent
nerve activation. This persistent activation of peripheral nociceptive signals creates an increased drive of
C-fiber afferent input to the spinal cord and release of SP and CGRP which, over time, leads to aberrant
functioning of CNS circuits and the symptoms of hyperalgesia and allodynia.

1.2.4. Animal Models of IC/BPS
Researchers rely on animal models to recapitulate the main pathophysiology of
IC/BPS to increase understanding of the mechanisms of the disorder as well as identify
potential targets for treatment interventions. There are three main types of animal models
for IC/BPS: 1) Bladder-centric models, 2) Complex mechanism models, and 3)
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Psychological and physical stressor/naturally occurring disease models (Birder and
Andersson 2018).
Bladder-centric models are used to model the effects of toxic metabolites from the
urine affecting deeper layers of the bladder wall. These models result in the hallmark
symptoms seen in IC/BPS: pain, inflammation, and urinary urgency/frequency (Bjorling,
Wang et al. 2011). These models are typically performed using toxic substances including
but not limited to acetic acid, hydrochloric acid, Bacillus Calmette-Gueirin (BCG),
lipopolysaccharide, xylene, mustard oil, or cyclophosphamide (CYP), either administered
systemically or infused directly into the bladder (Bjorling, Wang et al. 2011, Birder and
Andersson 2018). Chemical models of IC/BPS allow for control of the degree of
inflammation and the duration of the inflammation (acute vs. chronic), while allowing for
the assessment of treatments on the severity of inflammation and pain as well as the impact
on bladder voiding behaviors. Another, more recently established, bladder-centric model
involves genetically altering tight junction proteins in the bladder wall, like claudins and
uroplakins, which cause the urothelium to become porous and leaky to free ions (eg: K+)
and/or toxic metabolites in the urine that then affect afferent nerve terminals in the bladder
wall (Montalbetti, Rued et al. 2015, Montalbetti, Rued et al. 2017, Birder and Andersson
2018).
The most widely used bladder-centric model in the literature is IC/BPS induced by
CYP (hereafter referred to as CYP-induced cystitis). CYP is an anti-neoplastic alkylating
agent used in chemotherapy to treat several types of cancer (Olivar and Laird 1999).
Though CYP itself is inert, it is metabolized in the liver to phosphamide mustard and
acrolein, which are excreted into the urine and accumulate in the bladder (Olivar and Laird
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1999). This accumulation of toxic metabolites, especially acrolein, causes intense changes
to the urinary bladder that mimic changes seen in patients with IC/BPS (Olivar and Laird
1999). CYP-induced cystitis can be used as an acute bladder inflammation model, induced
with one intraperitoneal injection of CYP, or a chronic model, induced with a series of
lower dose intraperitoneal CYP injections over the course of several days (Birder and
Andersson 2018). Both models yield the hallmark symptoms of IC/BPS (pain and bladder
overactivity) while also inducing localized bladder specific pathological changes like
mucosal edema, urothelial breakdown, inflammatory cell infiltration, petechial
hemorrhaging, and afferent nerve hyperexcitability (Olivar and Laird 1999, Birder and
Andersson 2018). Though CYP induces a greater inflammatory response than seen in many
cases of IC/BPS, it is an appealing model in that it can be induced non-invasively, the
pathological changes are specific to the bladder, and the functional and molecular changes
can be reliably reproduced (Olivar and Laird 1999, Bjorling, Wang et al. 2011).
Models with complex mechanisms use a top-down approach and are not as widely
used as bladder-centric models because their value for translational treatments has not been
clearly identified. However, they do provide interesting insight into more central
mechanisms that drive the symptoms of IC/BPS. In brief, these models chemically alter
CNS circuits, typically via pseudorabies viral injections into the abductor caudalis dorsalis
tail base muscle (Birder and Andersson 2018). This then leads to a form of neurogenic
cystitis that results in increased pelvic pain and mast cell infiltration in the lamina propria
(Birder and Andersson 2018).
Psychological and physical stressor/naturally occurring disease models include
models of stress (water avoidance stress; WAS and repeated variate stress; RVS) as well
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as feline interstitial cystitis (FIC), a naturally occurring model that requires very little
manipulation to produce. FIC is the model most similar to IC/BPS experienced by patients.
This model successfully reproduces most facets of the pathology including peripheral and
central dysfunction that leads to the hallmark symptoms (pain and bladder overactivity) as
well as co-morbidities with other disorders, like irritable bowel syndrome (Westropp and
Buffington 2002). However, even given its similarities, the FIC model is not widely used
due to the scarce availability of the required animals as well as the lack of researcher control
due to the spontaneous nature of the disease in felines (Birder and Andersson 2018).
For this reason, stress models are commonly used as an alternative. Stress models
have been shown to induce pain behaviors in rodents along with bladder overactivity
(Smith, Leung et al. 2011, Merrill and Vizzard 2014, Wang, Chang et al. 2017).
Additionally, experiments with the WAS model have shown increased inflammatory cell
infiltration, urothelial breakdown, evidence of peripheral and central sensitization, and
increased blood flow to areas in the brain associated with voiding urgency (Wang, Chang
et al. 2017, Birder and Andersson 2018). Though the mechanisms of this are not known for
certain, research suggests that it is a consequence of aberrant functioning of the
hypothalamic-pituitary-adrenal (HPA) axis. As evidence for this, chronic stress has been
shown to increase sympathetic nerve activity which results in increased adrenergic
stimulation due to dysfunctional HPA feedback mechanisms to various stress hormones
(Birder and Andersson 2018). Though psychological stress models can recapitulate many
of the LUT and pain symptoms of IC/BPS, they are not easily replicated, and the data can
prove to be variable depending on the type of stress performed and the species/strain of
animal used (unpublished data).
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1.3. Vascular Endothelial Growth Factor (VEGF) Signaling
1.3.1. Parallel Between Nervous and Vascular System Development
Since the 1500’s, scientists have examined the anatomical parallels between nerve
and blood vessel patterning in the human body (Almodovar, Lambrechts et al. 2009).
Initially during development, neural and vascular network formation is distinct, but is not
without physiological similarities. Neurons send out long axonal projections, typically led
by a growth cone, to reach their intended targets. Once there, the axon arborizes allowing
it to innervate several target cells. These branches are continually pruned to refine the
projections to specific neurons and tissue types (Carmeliet and Storkebaum 2002). In
contrast to this, the vasculature develops more locally via proliferating endothelial cells
that form the main branches of the vascular system (Carmeliet and Storkebaum 2002). Like
growth cones, navigating blood vessels also have a “tip” that is responsible for sampling
the target environment and responding to guidance cues (Gerhardt, Golding et al. 2003).
Once in the target environment, smaller, side branches of vessels are then created through
a process called angiogenesis, which requires migration of local endothelial cells to the site
of the main vessel (Carmeliet and Storkebaum 2002). Throughout the course of
development, as angiogenesis increases the amount of vessel sprouting, several of the
smaller, branching vessels are pruned or combined to yield the mature vascular system
(Carmeliet and Storkebaum 2002).
Though both serve different physiological purposes, the two systems also share
similarities in their patterning, such that blood vessels tend to run alongside nerves
throughout the body (Almodovar, Lambrechts et al. 2009). In some instances, axons
respond to signals released by blood vessels, like artemin and neurotrophin 3, and follow
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the path of main branches of blood vessels (Honma, Araki et al. 2002, Kuruvilla, Zweifel
et al. 2004). In other instances, blood vessels follow the path of nerves through signals
released by neurons, such as vascular endothelial growth factor (VEGF; Mukouyama, Shin
et al. 2002). Chapter 2 of this dissertation will focus on the molecular and functional role
of VEGF and its signaling in the pathogenesis of IC/BPS.
1.3.2. VEGF and its Receptors
VEGF-A, hereafter referred to as VEGF, belongs to the cysteine knot family of
growth factors that includes placenta growth factor, VEGF-B, VEGF-C, and VEGF-D
(Tammela, Petrova et al. 2005). In humans, VEGF is localized on chromosome 6p21.3 and
is comprised of 8 exons separated by 7 introns. Due to alternative splicing, VEGF has four
main proteolytic isoforms in humans with 121, 165, 189, and 206 amino acids each
(VEGF121, VEGF165, VEGF189, VEGF206, respectively; Houck, Ferrara et al. 1991, Tischer,
Mitchell et al. 1991). In mice, each isoform is one amino acid shorter (VEGF120, VEGF164,
VEGF188, VEGF205; Mackenzie and Ruhrberg 2012). All isoforms contain exons 1-5 but
they differ in their coding of exons 6 and 7, such that they may be absent in some isoforms.
Additionally, most functional isoforms contain exon 8 which is crucial for carrying out
endothelial cell proliferation (Medford, Douglas et al. 2009). Given the differences in their
genetic coding, the roles of these isoforms are unique, primarily due to differences in
heparin affinity (encoded by exons 6 and 7) which leads to differing interactions with the
extracellular matrix and VEGF receptors (Park, Keller et al. 1993, Yamazaki and Morita
2006). Because of this, expression of each isoform varies depending on tissue type, though
VEGF165 is the most abundant isoform in humans (Ng, Rohan et al. 2001). Lesser-known
splice variants have also been discovered including, VEGF145 (Poltorak, Cohen et al. 1997),
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VEGF183 (Jingjing, Xue et al. 1999), VEGF162 (Lange, Guttmann-Raviv et al. 2003), and
an inhibitory variant with effects that oppose VEGF, VEGFxxxb (Bates, Cui et al. 2002),
where “xxx” denotes the number of amino acids in the mature isoform.
All VEGF isoforms signal through two transmembrane tyrosine kinase receptors
called VEGFR1 (fms-like tyrosine kinase 1; Flt-1) and VEGFR2 (fetal liver kinase 1; Flk1; Ferrara 2001). Like a loss of VEGF itself, loss of either receptor is embryonically lethal
due to improper blood vessel development (Ruhrberg 2003). VEGFR2 is highly
homologous with VEGFR1 and even though it has a slightly lower affinity for VEGF,
VEGFR2 is the main signaling receptor (Terman, Dougher-Vermazen et al. 1992). Binding
of VEGF to VEGFR2 promotes vascular permeability, as well as proliferation and
migration, leading to blood vessel angiogenesis via activation of the phosphatidylinositol
3-kinase (PI3K) and Akt as well as extracellular signal-regulated kinase-1 and -2 (ERK1
and ERK2), protein kinase C, and protein kinase D signaling cascades (Gerber, McMurtrey
et al. 1998, Takahashi, Yamaguchi et al. 2001, Evans, Britton et al. 2008). The role of
VEGF signaling through VEGFR1 is less clear. Upon binding VEGF, VEGFR1 is weakly
autophosphorylated suggesting that it may function as a decoy receptor, primarily binding
VEGF to prevent it from binding and activating VEGR2 (Park, Chen et al. 1994). Other
research suggests that VEGFR1 may play a larger role in monocytes and macrophages as
activation of VEGFR1 via VEGF leads to increased migration of these specific cell types
(Barleon, Sozzani et al. 1996).
In addition to VEGFR1 and VEGFR2, VEGF165 as well as other members of the
cysteine knot family of growth factors, can bind to co-receptors called neuropilins (NRP),
specifically, NRP1 and NRP2 (Appleton, Wu et al. 2007, Pan, Chathery et al. 2007). Both
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receptors are transmembrane glycoproteins that bind class 3 semaphorins, VEGF and
VEGF-C to mediate the signaling role of these factors in endothelial, lymphatic, and
neuronal cells. NRP1 and NRP2 lack enzymatic activity upon binding their ligand,
therefore, their role is postulated to be increasing the affinity of VEGF to VEGFR2 and
VEGF-C to VEGFR3. As evidence of this, specifically in endothelial cells, VEGF
promotes the formation of a complex with NRP1 and VEGFR2 that is suggested to be
important for optimal VEGF function and downstream signaling (Soker, Miao et al. 2002).
As a result of this complex, NRP1 enhances the activity of VEGFR2 up to six times which
has a profound effect on influencing angiogenesis and vascular permeability (Hoeben,
Landuyt et al. 2004, Melincovici, Bosca et al. 2018). NRP2 has been shown to specifically
increase VEGF-C binding to VEGFR3 enhancing signals related to lymphogenesis
(Herzog, Kalcheim et al. 2001, Melincovici, Bosca et al. 2018).
1.3.3. Functional Role of VEGF in the Nervous System
VEGF signaling is driven by various cues; canonically, these cues are all related to
increasing VEGF expression during hypoxia to stimulate angiogenesis. When an organ is
hypoxic, it releases transcription factors to stimulate blood vessel growth to increase the
necessary supply of oxygen to that tissue. These factors include hypoxia-inducible factors
(HIFs) that then induce the expression of angiogenic factors, mainly VEGF (Almodovar,
Lambrechts et al. 2009). VEGF is the most potent stimulator of angiogenesis, though its
physiological role does not end there. Along with angiogenesis, VEGF is released from
various cell types (including but not limited to endothelial cells, neurons, tumor cells,
macrophages, activated T-cells, leukocytes, and astrocytes) to induce cell proliferation,
vasodilation, and recruitment of inflammatory cells (Ferrara 2004, Takahashi and Shibuya
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2005, Koch, Tugues et al. 2011, Melincovici, Bosca et al. 2018). Furthermore, recent
studies have revealed numerous roles of VEGF within the nervous system; this section will
expand upon that role in both the CNS and PNS.
VEGF has several roles at the intersection of the vascular and nervous systems (eg:
cerebral angiogenesis, and neuronal patterning), however, apart from that, VEGF has been
shown to act as a trophic factor in the nervous system independent of vascular influence
(Rosenstein, Krum et al. 2010). In support of this, application of VEGF stimulated neurite
outgrowth and enhanced neuronal survival in cerebral cortex brain explants, spinal cord
explants, and in cultured DRG neurons (Silverman, Krum et al. 1999, Sondell, Lundborg
et al. 1999, Sondell, Sundler et al. 2000, Rosenstein, Mani et al. 2003, Rosenstein, Krum
et al. 2010). Though many VEGF effects on neurons may be indirect and mediated by
various glial cells, research has shown increased neurite outgrowth in cultures of primary
cortical neurons, which suggests VEGF has a direct neurotrophic role that can function
independently of the presence of glia (Rosenstein, Mani et al. 2003, Khaibullina,
Rosenstein et al. 2004). In addition to its role in increasing neurite outgrowth, VEGF has
been shown to influence neuronal plasticity in the CNS. Through modulation of expression
of calcium/calmodulin protein kinase II (CaMKII), cAMP-responsive element binding
protein (CREB), and mammalian target of rapamycin (mTOR) at the level of the synapse,
VEGF has been implicated in inducing protein synthesis that affects synapse efficiency in
the hippocampus leading to increases in long-term potentiation (Kim, Choi et al. 2008).
VEGF also has neuroprotective effects via VEGFR2 from stimuli including hypoxia, serum
withdrawal, and excitotoxicity, in neurons of the CNS and PNS (Almodovar, Lambrechts
et al. 2009). Moreover, VEGFR2 has been shown to mediate VEGF effects on
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resulting

in

neuroregeneration may be a secondary effect of VEGF- mediated angiogenesis and the
subsequent effects of reperfused tissue (Almodovar, Lambrechts et al. 2009).
Given its diverse neurological roles, VEGF has been implicated in several
pathologies and can have both positive and negative effects in the nervous system
depending on the context. For example, though VEGF signaling exerts positive effects by
increasing neuroprotection and regeneration after an ischemic related injury, it has also
been implicated in the worsening of inflammation as well as increasing the permeability of
the blood brain barrier (Silverman, Krum et al. 1999, Mani, Khaibullina et al. 2005). In
Multiple Sclerosis (MS), specifically during the inflammatory phase, VEGF and VEGFR1
are shown to be upregulated in astrocytes in lesions in a murine model of MS. In addition,
intrastriatal infusion of VEGF increases plaque inflammation at the injection site
(Proescholdt, Jacobson et al. 2002). In contrast to that, administration of recombinant
soluable-VEGFR1 to rats with experimental autoimmune encephalomyelitis, a model of
MS, showed a decrease in the number of inflammatory cells in the CNS (Zhu, Hu et al.
2008). This suggests that VEGF signaling may possess a dual role in the pathology of MS,
depending on the receptor it signals through as well as the phase of the disease in which it
is given. A similar phenomenon is seen in spinal cord injury (SCI). Immediately following
SCI, VEGF and VEGF receptor expression are increased which leads to axonal
regeneration and decreased neuronal apoptosis, which both contribute to increased
functional recovery (Sköld, Cullheim et al. 2000, Widenfalk, Lipson et al. 2003, Choi, Kim
et al. 2007, Patel, Cohen et al. 2009). However, even given these beneficial effects, VEGF
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therapy has also been shown to worsen SCI outcomes in other studies due to its effects on
increasing vascular permeability (Benton and Whittemore 2003).
1.3.4. Role of Regulatory Gene Expression in Chronic Pain
In addition to neurological conditions, VEGF has been implicated in diseases like
diabetes, arthritis, and cancer, all of which have a large chronic pain component. For
instance, in diabetic patients, sensitization of neurons in the CNS and PNS leads to
hyperactive nerves and symptoms of hyperalgesia (Hulse 2017). Research suggests that
VEGF contributes to these neuropathic pain symptoms by inducing sensory neuron
outgrowth and survival, which in part leads to nerve overactivity (Beazley-Long, Hua et
al. 2013). Though the precise mechanisms of VEGF in the pathophysiology of pain is still
widely unknown, its association with the sensory components of these disorders warrants
further research since chronic pain treatments are severely lacking.
One hypothesis for the involvement of VEGF in chronic pain conditions involves
the alternative splicing of VEGF. Recall that VEGF has several physiological isoforms, all
with a different number of amino acids depending on the splice site. To build on that,
depending where, specifically on exon 8, VEGF is spliced, two families of isoforms are
yielded: VEGFxxxa (proximal exon 8 splice site) and VEGFxxxb (exon 8b distal splice site;
Harper and Bates 2008). Many VEGF isoforms of varying amino acid lengths can yield
the “a” and “b” isoforms, therefore, “xxx” denotes the number of amino acids in the mature
protein. The “a” and “b” isoforms differ only in their six C’ terminal amino acids, but they
have been found to have directly opposing functions. Namely, VEGFxxxa isoforms are proangiogenic while VEGFxxxb isoforms are anti-angiogenic (Perrin, Konopatskaya et al.
2005, Harper and Bates 2008). Moreover, research suggests that alternative splicing of
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VEGF is dysregulated in pathologies related to chronic pain (Hulse 2017). As evidence of
this, in a rodent model of neuropathic pain, VEGFR2 was shown to be expressed and
activated on both Aδ- and C-fiber nociceptors (Hulse, Beazley-Long et al. 2014, Hulse,
Drake et al. 2016, Hulse 2017). Activation of VEGFR2 in this model was correlated with
an increase in VEGFxxxa and a decrease in VEGFxxxb expression, as a proportion of total
VEGF, in the periphery (DRG and skin) as well as in the spinal cord (Hulse, Beazley-Long
et al. 2014, Hulse, Drake et al. 2016). Further research suggests this differential regulation
results in functional differences via interactions with TRPV1 such that VEGF165a
potentiates TRPV1 induced sensory neuronal responses while VEGF165b suppresses
TRPV1 activation (Hulse, Beazley-Long et al. 2014). This leads to the conclusion that
VEGFxxxa produces algesia whereas VEGFxxxb signaling is analgesic.
Understanding VEGF alternative splicing is crucial for the discovery of new
treatments for chronic pain. Based on the existing data, new therapeutics could arise from
biasing VEGF alternative splicing away from VEGFxxxa and towards VEGFxxxb. One way
to do this is to target serine-arginine rich protein kinase 1 (SRPK1) which facilitates the
phosphorylation of serine-arginine rich splice factor (SRSF1) which leads to an increased
production of VEGFxxxa (Hulse, Beazley-Long et al. 2014, Hulse, Drake et al. 2016). Given
this, one study showed that an inhibition of SRPK1 decreased the production of VEGFxxxa
and increased production of VEGFxxxb which functionally reduced pain behaviors in a rat
model of neuropathic pain (Hulse, Drake et al. 2016).
1.3.5. VEGF and IC/BPS
Over the last 15 years, the role of VEGF in the bladder and specifically in IC/BPS,
has been under investigation. In uninflamed bladders of both rodents and humans, VEGF
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and its receptors are expressed in the vasculature of the bladder as well as in the urothelium
(specifically in the superficial umbrella cells), the detrusor, and the neuronal cells in pelvic
ganglia (Cheppudira, Girard et al. 2008, Saban, Backer et al. 2008, Saban, Saban et al.
2008). Using several different IC/BPS animal models, research consistently shows
upregulation of VEGF compared to normal bladders (Cheppudira, Girard et al. 2008,
Saban, Backer et al. 2008, Saban, Saban et al. 2008). Furthermore, VEGF expression is
also increased in bladder biopsy samples from patients that fit the diagnostic criteria for
IC/BPS (Kiuchi, Tsujimura et al. 2009). This increase in VEGF seen in patients with
IC/BPS is further correlated with an increase in pain severity (Kiuchi, Tsujimura et al.
2009).
Given the expression profiles of VEGF in the urinary bladder and the expression
changes due to inflammation, research has sought to understand the specific mechanism
that underlies the role of VEGF in bladder inflammation. An understanding of this
mechanism could lead to much needed treatments and/or a biomarker to aid in improving
IC/BPS diagnostics. One hypothesis involves the impact of angiogenesis on IC/BPS
pathophysiology. Though not a disease criterion according to several accepted clinical
definitions, several patients that present with IC/BPS symptoms have vascular alterations
including bladder wall glomerulations (i.e.: Hunner’s ulcers/lesions). These glomerulations
are indicative of fragile blood vessels that become hemorrhagic. This is thought to originate
in the urothelium, and subsequently spread to deeper layers of the bladder wall (Andersson
and Hedlund 2002, Járomi, Szabó et al. 2012). Canonically, VEGF is increased in hypoxic
environments in response to HIFs to promote angiogenesis and provide the tissue with
oxygen. In bladder biopsies of patients with IC/BPS, HIF-1α has been shown to be
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increased, which leads to an overexpression of VEGF in umbrella cells of the urothelium
(Lee and Lee 2011). Such high levels of VEGF have been associated with immature
vascularization characterized by diminished pericyte coverage of microvessels that can
lead to the hemorrhagic blood vessels and the glomerulations seen in IC/BPS (Kiuchi,
Tsujimura et al. 2009).
As previously stated, nerve and blood vessel development share several
overlapping characteristics, such as similar patterning during development and shared
responses to molecular mediators (Martin and Lewis 1989, Saban, Davis et al. 2011).
Therefore, increasing evidence suggests that in addition to an angiogenic factor on blood
vessels, VEGF may have act as a trophic factor on nerve cells in the bladder and promote
sensory nerve plasticity. Several other trophic factors, like NGF, have previously been
implicated in bladder sensory nerve plasticity in models of IC/BPS (Vizzard 2000). Though
a distinct mechanism for VEGF as a trophic factor in the bladder is unknown, a similar
phenomenon has been shown in other tissues outside of the bladder, such that
administration of VEGF promoted regeneration of sciatic nerve fibers following a
transection of the nerve, most likely through a combination of angiogenic, neurotrophic,
and neuroprotective effects (Pereira Lopes, Lisboa et al. 2011). In 2011, Saban, et al.
showed that infusing a VEGF neutralizing antibody directly into the bladder attenuated
sensory nerve plasticity that was induced in an animal model of IC/BPS (Saban, Davis et
al. 2011). Moreover, in a paper from the same lab the following year, Malykhina, et al.
confirmed these results by showing an increase in TRPV1 positive sensory nerve fibers in
the urinary bladder after instillation of VEGF (Malykhina, Lei et al. 2012).
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VEGF has also been implicated in the functional changes seen in IC/BPS.
Following instillation of VEGF into the urinary bladder, mice showed functional decreases
in several urinary voiding parameters such as micturition volume, intermicturition interval,
and bladder capacity, as measured by conscious cystometry (Malykhina, Lei et al. 2012).
A separate cohort of mice with VEGF instillation also showed increased visceral sensitivity
as measured by Von Frey filament testing, a common mechanical pain assay (Malykhina,
Lei et al. 2012). This increase in pain may be due to a separate finding that showed that
voltage-gated Na+ channels were upregulated in DRG neurons harvested from these
VEGF-treated mice (Malykhina, Lei et al. 2012). This result was further corroborated in
2017 by research from the MAPP that showed that pelvic nociceptive responses were
reduced in mice with CYP-induced cystitis following pre-treatment of systemic
administration of VEGF neutralizing antibodies (Lai, Shen et al. 2017). Together, these
results suggest a role of VEGF in IC/BPS however, additional research in VEGF signaling
in the bladder is needed before declaring VEGF signaling a viable therapeutic target for
IC/BPS treatment.
1.4. Piezo1 and Mechanotransduction in the Bladder
1.4.1. Background on Mechanotransduction
Mechanotranduction, the conversion of mechanical forces into biological signals,
is an essential physiological process used throughout the body, though the mechanism of
mechanosensing is still largely unknown and is currently being investigated in several
organ systems (Nilius 2010). In the urinary bladder, mechanotransduction is the
mechanism used to convert signals related to bladder distention into sensory signals that
relay the level of bladder fullness to the spinal cord and higher order brain centers that
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integrate that information to determine an appropriate time to void. Increasing evidence
suggests that mechanosensitive ion channels on urothelial cells can also be activated by
numerous diverse signals including bladder stretch, temperature changes, pH changes, and
chemical irritation. Once activated, the urothelial cells transduce these signals to bladder
afferent nerves by releasing chemical mediators, such as ATP (Olsen, Stover et al. 2011,
Birder and Andersson 2013).
Research is ongoing to determine which mechanosensitive channels are responsible
for transducing this signal and the mechanism by which they carry out this function.
Calcium-permeable stretch-activated cation channels (SACs) were discovered over 20
years ago and research suggests they are the main drivers of mechanotransduction. SACs
can be classified into channels that are directly gated or indirectly gated. An ion channel
that has direct gating is the primary transducer of mechanical force, meaning that it alone
senses the force and passes on a receptor current. A channel with indirect gating plays a
necessary role in mechanical transduction but does so by second messenger signaling via
G-proteins, phospholipases, and/or the activation of downstream kinases (Christensen and
Corey 2007, Nilius 2010). For a channel to be considered directly mechanosensitive, the
candidate ion channel must meet several functional criteria as defined by Christensen and
Corey: 1) The latency of the current elicited by the stimulus should be faster than known
second-messenger systems (i.e.: less than 5 milliseconds), 2) The kinetics of channel
activation should be proportional to the amplitude of the stimulus such that a larger
mechanical force leads to faster opening of the channel, 3) There should be a mechanical
correlate of channel-gating (eg: observable movement) in the sensory cell or organ that
responds in the same range as the stimuli that leads to an opening of the channel, 4) Part of
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the channel or an associated subunit of the channel needs to move in response to the
mechanical force as evidence of direct gating, and 5) The candidate protein must contain
an ion channel pore (Christensen and Corey 2007).
Given these criteria, research suggests the presence of several mechanosensitive
ion channels on urothelial cells that respond to mechanical stretch of the bladder, among
other signals. For instance, the TRP family of channels are non-specific cation channels,
mostly permeable to Ca2+, that are involved in mechanosensation throughout the body
(Moran, McAlexander et al. 2011, Moore and Liedtke 2017). Several of the channels in
this family are sensors of stretch as well as noxious stimuli, though TRPV1 and TRPV4
seem to both have important implications for the regulation of ATP release from urothelial
cells in response to bladder stretch (Birder, Nakamura et al. 2002, Gevaert, Vriens et al.
2007, Girard, Campbell et al. 2019). Evidence of this comes from studies that show
addition of TRPV1 and TRPV4 agonists onto urothelial cell cultures increases ATP release
from these cells, while the addition of antagonists decreases ATP release (Birder,
Nakamura et al. 2002, Birder, Kullmann et al. 2007, Girard, Campbell et al. 2019). This
decrease in ATP release after application of a TRPV1 antagonist was mirrored by impaired
stretch evoked responses in bladders from TRPV1−/− mice along with low-amplitude
bladder activity resulting in increased bladder capacity (Birder, Nakamura et al. 2002).
Additionally, in a study from our lab in 2019, we showed attenuated ATP release with
TRPV4 inhibition. Moreover, using an intravesical TRPV4 antagonist (HC-067047)
infusion, we showed functional bladder improvements and a decrease in pelvic
hypersensitivity in a model of pelvic pain and bladder overactivity in mice (Girard,
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Campbell et al. 2019). These results underscore the potential of targeting mechanosensitive
ion channels for treatment of bladder overactivity and pain.
1.4.2. Structure and Function of the Piezo Channels
Like TRPV4, Piezo1 and Piezo2 are mechanically gated ion channels that use
mechanotransduction to convert mechanical force into cellular signals. Upon their
discovery in a Neuro2A mouse cell line in 2010, Piezo proteins have been shown to induce
mechanically activated currents in numerous mammalian cell types in response to
physiological stimuli like touch, pressure, and stretch (Coste, Mathur et al. 2010).
Compared to similar ion channels, both Piezo channels are uniquely large (>2000 amino
acids) and have numerous transmembrane domains (24-40; Coste, Mathur et al. 2010).
Piezo1 forms homotrimers and like other SACs, Piezo1 has an ion-conducting pore
(Bagriantsev, Gracheva et al. 2014). Cryo-electron microscopy has revealed that the
structure of Piezo1 is “propeller-like” in that it has a centralized pore that is surrounded by
three peripheral domains called “blades” (Botello-Smith, Jiang et al. 2019). Researchers
hypothesize that these blades are responsible for sensing and responding to the local
curvature of the lipid bilayer, and though the exact mechanism remains to be elucidated, it
appears that the blades play a central role in transferring force from membrane tension to
the pore directly by way of a lever-like mechanism. Given this, it is suspected that Piezo1
can directly sense lipid membrane extension and does not require additional proteins to
open the ion pore (Gottlieb and Sachs 2012, Guo and MacKinnon 2017, Saotome, Murthy
et al. 2018, Wang, Chi et al. 2018, Zhao, Zhou et al. 2018, Botello-Smith, Jiang et al. 2019).
Though Piezo1 and Piezo2 share ~50% identity, they are functionally distinct and are
differentially expressed in tissues throughout the body. For example, Piezo1 is found in
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high levels in the skin, kidneys, lungs, and urinary bladder, while Piezo2 is predominantly
expressed in sensory neurons in the trigeminal ganglia, DRG, and Merkel cells, as well as
in lower levels in the lungs and urinary bladder (Coste, Mathur et al. 2010). Additionally,
the inactivation kinetics of the Piezo channels differ, such that Piezo2 is inactivated more
rapidly than Piezo1 (Coste, Mathur et al. 2010).
1.4.3. Pharmacological Manipulation of Piezo1
Unlike Piezo2, Piezo1 can be pharmacologically manipulated by commercially
available synthetic small molecules. An activator of Piezo1 called Yoda1 was identified
using high-throughput screening, and is the most potent agonist of Piezo1, with a half
maximal effective concentration (EC50) of 10-50µM (Wang, Chi et al. 2018, BotelloSmith, Jiang et al. 2019). Though research is ongoing, a recent study by Botello-Smith, et
al. found three potential Yoda1 binding sites on the Piezo1 protein, which makes sense
given that Piezo1 is a homotrimer. However, somewhat unexpectedly, their actual model
showed only one single Yoda1 binding site on the channel. This may be due to the
asymmetry or different conformations of each subunit at any given time (Saotome, Murthy
et al. 2018, Zhao, Zhou et al. 2018, Botello-Smith, Jiang et al. 2019). Regardless, Yoda1
has been shown to bind to Piezo1 and act as a “molecular wedge” to induce specific
conformational changes within the channel and facilitate the opening of the ion pore
(Botello-Smith, Jiang et al. 2019). To support this, other studies have found that Yoda1
alters the movement of the Piezo1 blade subunits and consequently lowers the mechanical
threshold for the activation of the channel (Syeda, Xu et al. 2015, Botello-Smith, Jiang et
al. 2019).
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Presently, there are no selective inhibitors for Piezo1. However, a peptide isolated
from tarantula venom, Grammostola spatulate, called GsMTx4 is a selective inhibitor for
all SACs (Suchyna, Tape et al. 2004, Bowman, Gottlieb et al. 2007, Gottlieb, Suchyna et
al. 2007). To inhibit these channels, GsMTx4 functions as a gating modifier by binding
within the lipid bilayer and biasing the ion channel to its closed conformation by increasing
the membrane tension required for SAC activation (Suchyna, Tape et al. 2004). Importantly
for the purposes of this dissertation, research by Bae, et al. have confirmed that GsMTx4
acts as a gating modifier by stabilizing the closed state of the Piezo1 channel and
successfully alters the kinetics of channel opening (Bae, Sachs et al. 2011).
1.4.4. Piezo1 Function Throughout the Body
Piezo1 is functionally imperative for survival; complete genetic knockdown of
Piezo1 is lethal during early embryogenesis due to impaired blood flow that results in
defects in vascular formation in the embryo and yolk sac (Ranade, Qiu et al. 2014). Given
this, numerous research studies highlight the role of Piezo1 in vascular biology. When
functioning properly, Piezo1 contributes to the mechanotransduction of endothelial cells in
normal conditions, though it is also implicated in conditions of increased hydrostatic
pressure and shear stress. Mechanistically, as pressure in blood vessels increases, Piezo1
is activated by the increased tension on the endothelial cells (Kubicek, Kopacik et al. 2010,
Bagriantsev, Gracheva et al. 2014, Li, Hou et al. 2014, Ranade, Qiu et al. 2014, Swain and
Liddle 2020). When this occurs, Piezo1 activation can mediate vasodilation that helps to
control vascular tone and blood pressure via ATP release through pannexin-1 and
subsequent downstream release of vasodilatory factors (Wang, Chennupati et al. 2016).
However, when blood pressure is clinically elevated in pulmonary blood vessels, for
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example, endothelial remodeling and increased permeability of the endothelial barrier can
occur due to loss of adherens junctions between the endothelial cells. Recent evidence
postulates that this may be mediated in part by Piezo1 activation and subsequent Ca2+ influx
that leads to internalization and degradation of VE-cadherin by a Ca2+-dependent protease
(Friedrich, Hong et al. 2019). This opens the door for future clinical therapies to target
Piezo1 signaling to reduce blood vessel stress in response to elevated pressure.
An additional role of Piezo1 signaling was recently identified in the pancreas. The
pancreas is unusually sensitive to mechanical injury, such that surgeons try to avoid
manipulating the pancreas during surgery to prevent the onset of acute pancreatitis (Romac,
Shahid et al. 2018). However, more typically, this injury is induced by increased pressure
within the pancreatic duct which insinuates that the pancreas itself must have a mechanism
to perceive this mechanical force (Romac, Shahid et al. 2018). Romac, et al. discovered
both mRNA and protein expression of Piezo1 in pancreatic acinar cells, in which the latter
was specifically localized to the plasma membrane (Romac, Shahid et al. 2018). Using the
Piezo1 agonist Yoda1 (25 µM), they showed that Piezo1 activation led to increased
intracellular Ca2+ concentration which facilitated acinar cellular death. Infusion of Yoda1
(0.4 mg/kg) into the pancreatic duct in vivo induced edema and histological features
consistent with acute pancreatitis compared to a vehicle infusion. This effect was further
supported to be Piezo1 mediated using Piezo1-/- mice that showed no difference in levels
of inflammation with Yoda1 or vehicle infusion (Romac, Shahid et al. 2018).
Piezo1 signaling is certainly not limited to the vasculature and the pancreas. Other
functions of Piezo1 include maintenance of epithelial homeostasis and cell division
(Eisenhoffer, Loftus et al. 2012, Gudipaty, Lindblom et al. 2017), volume regulation of red
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blood cells (Faucherre, Kissa et al. 2014, Cahalan, Lukacs et al. 2015), bone formation
(Sun, Chi et al. 2019), facilitation of neuronal axon growth (Koser, Thompson et al. 2016),
and neural stem cell differentiation (Pathak, Nourse et al. 2014). Most of the research into
Piezo1 has occurred recently, within the last 5 years. As additional genetic models and
pharmacological activators and inhibitors of Piezo1 are established, the widespread
physiological role of Piezo1 in vivo will continue to be revealed across tissue types. This
research will help to inform the translational potential of targeting Piezo1 signaling
throughout the body.
1.4.5. Piezo1 Expression and Function in the Urinary Tract
Like other tissues and cell types that express Piezo1, the urinary tract, and
especially the urinary bladder, have a unique need to use mechanotransduction to function
properly. Specifically, the bladder must be able to transduce the level of distension and
pressure into a sensory signal to relay this information to the CNS. Experiments using
Piezo1-tandem-dimer Tomato (tdT) mice have shown Piezo1 gene expression in several
tissues within the urinary tract including several structures within the kidneys, ureter,
prostate, seminal vesicles, ejaculatory ducts, the pelvic urethra (females) and prostatic
urethra (males), and the urinary bladder (Dalghi, Clayton et al. 2019). More specifically,
Piezo1 gene expression is found throughout all layers of the urinary bladder wall. In the
urothelium, Piezo1 mRNA is localized to all three layers (umbrella, intermediate, and basal
cells). In the lamina propria, Piezo1 mRNA is specifically expressed by interstitial cells
that also express platelet-derived growth factor receptor alpha (PDGFR-α). In the detrusor
smooth muscle layer, Piezo1 mRNA is predominantly found surrounding smooth muscle
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cells, presumably associated with the sarcolemma of these cells, in addition to the
interstitial cells within the detrusor (Dalghi, Clayton et al. 2019).
Experiments conducted using in situ hybridization found similar Piezo1 gene
expression results, though notably, they found that Piezo1 mRNA was predominantly
localized to the urothelium and was expressed in the detrusor to a much lesser extent
(Miyamoto, Mochizuki et al. 2014). This same study assessed Piezo2 gene expression and
found minimal expression in several urinary tract associated tissues (bladder, ureter, and
kidney; Miyamoto, Mochizuki et al. 2014). Studies examining Piezo1 protein expression
via immunohistochemistry and immunocytochemistry revealed Piezo1 localization to the
urothelial layer, similar to both previous gene expression assays, as shown by co-staining
with cytokeratin-7, an intermediate filament protein marker of urothelial cells (Miyamoto,
Mochizuki et al. 2014).
Like other SACs in the urothelium, stretch, activation of Piezo1 leads to an increase
in intracellular calcium concentration ([Ca2+]i) which results in ATP release. In support of
this, in cultured urothelial cells, mechanical stretch stimulation via a cell extension device
led to an increase in [Ca2+]i and release of ATP that was significantly decreased in cells
treated with siRNA against Piezo1, or the SAC inhibitor, GsMTx4 (Miyamoto, Mochizuki
et al. 2014). Notably, this ATP release is directly dependent on the influx of Ca2+ since the
same experiments conducted in the absence of extracellular Ca2+ showed dramatic
suppression of ATP release in both the control and Piezo1 knockdown/inhibited urothelial
cells (Miyamoto, Mochizuki et al. 2014).
In addition to its role in normal micturition function, Piezo1 has also been
implicated in animal models of pathological urinary bladder conditions like partial bladder
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outlet obstruction (pBOO) and IC/BPS. Specifically, in a rat model of pBOO, Piezo1 gene
expression was upregulated compared to controls in the suburothelial and detrusor layers
of the bladder wall (Michishita, Yano et al. 2016). In a CYP-induced cystitis rat model of
IC/BPS, Piezo1 protein and mRNA expression were both upregulated compared to controls
in the whole bladder after intermediate (48 h) and chronic inflammation (8 d), but not acute
(4 h) inflammation (Liu, Sun et al. 2018). Functionally, administration of GsMTx4 in
unconscious naïve (no CYP) rats and rats treated with chronic CYP led to an increase in
the intercontraction interval and a decrease in maximum bladder pressure, which suggests
that blocking SACs, including Piezo1, increases functional bladder outcomes (Liu, Sun et
al. 2018).
1.4.6. Piezo1 and the Inflammatory Response
There may be several ways in which SAC activation contributes to pathological
bladder symptoms. Several research studies show that activation of Ca2+ permeable ion
channels in the urinary bladder, including TRPV4, contribute to maladaptive changes
following CYP-induced cystitis, while inhibition of these channels promote improved
bladder functional outcomes (Thorneloe, Sulpizio et al. 2008, Everaerts, Zhen et al. 2010,
Aizawa, Wyndaele et al. 2012, Zhang, Gao et al. 2017, Girard, Campbell et al. 2019).
Research in the bladder, as well as in other organ systems, suggest that aberrant activation
of channels that regulate [Ca2+]i may increase the physiological inflammatory response.
For example, administration of Carbenoxolone, a drug used to inhibit channels that regulate
Ca2+, attenuated CYP-induced increases in several inflammatory mediators like COX-2,
phospho-p38, and iNOS, while simultaneously improving functional bladder outcomes, as
evidenced by a decrease in voiding frequency (Zhang, Gao et al. 2017). TRPV4 has also
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been implicated in the inflammatory effects following SCI as illustrated by dramatic
increases in proinflammatory cytokine mRNA in the spinal cord including, IL-6, IL-1β,
TNF-α, CCL2, and CCL3, that were all attenuated in a TRPV4-/- mouse model (Kumar,
Lim et al. 2020). In a mouse model of sepsis, TRPV4 antagonism or knockdown increased
survival by 60-70% by decreasing the blood concentration of various pro-inflammatory
cytokines (IL-6, IL-1 α, and TNF-α; Dalsgaard, Sonkusare et al. 2016). Lastly, research in
mouse fetal lungs has shown that stretch-induced activation of TRPV4 leads to IL-6
production via activation of the p38 and ERK cell signaling pathways (Nayak, Wang et al.
2015)
Though SACs like TRPV4 have been widely studied in the bladder as well as
numerous organ systems, the effects of Piezo1 activation on the inflammatory milieu have
not yet been studied in the bladder. However, in cardiac fibroblasts, chemical activation of
Piezo1 and subsequent Ca2+ influx resulted in increased mRNA and protein expression of
IL-6 via downstream activation of p38 (Blythe, Muraki et al. 2019). Furthermore, in
nucleus pulposus cells, mechanical activation of Piezo1 was shown to mediate
inflammation through the activation of the NOD-like receptor protein 3 (NLRP3)
inflammasome and the production and secretion of IL-1β (Sun, Leng et al. 2020).
Currently, the role that Piezo1 activation plays in perpetuating the inflammatory response
in the urinary bladder during IC/BPS is unknown.
1.5. Project Goals and Hypotheses
IC/BPS is a pathology of unknown etiology characterized by the hallmark
symptoms of severe pelvic pain and bladder dysfunction, specifically increased frequency
and urgency of voiding. It is estimated that as many as 6.5% of women and 4.2% of men
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meet IC/BPS diagnostic criteria. In individuals with this pathology, urothelial barrier
breakdown and subsequent bladder inflammation is followed by chronic activation of
afferent nerve terminals that then leads to hyperalgesia and allodynia via neurogenic
inflammation induced peripheral and central sensitization. Due to the diverse signaling
molecules, channels, and receptors present on urothelial cells as well as afferent nerves in
the bladder, there are numerous potential mediators of IC/BPS induced bladder
dysfunction. The goal of this dissertation is to examine several potential mediators of
bladder dysfunction in CYP-induced cystitis, a bladder-centric animal model of IC/BPS.
In Chapter 2, we examine the role of VEGF in bladder function and dysfunction in
male and female rats with and without CYP-induced cystitis. Further, we examine changes
in VEGF mRNA splice variant expression in LUT-associated tissues of animals with and
without CYP-induced cystitis. Our hypothesis was that inhibition of VEGF signaling
through its receptor, VEGFR2 would improve bladder functional outcomes in animals with
CYP-induced cystitis. Further, we hypothesized a change in VEGF splice variant mRNA
expression dependent on tissue type as well as duration of treatment with CYP.
In Chapter 3, we examine the role of Piezo1, a Ca2+-permeable mechanosensitive
ion channel, in bladder function and dysfunction of female rodents with and without CYPinduced cystitis. We hypothesized that Piezo1 expression would increase in LUTassociated tissues in animals treated with CYP. Further, we hypothesized that activation of
Piezo1 would lead to an increase in voiding frequency. Mechanistically, we hypothesized
that Piezo1 activation would lead to increased Ca2+ activity in urothelial cells which may
then promote changes in the inflammatory milieu of the bladder and the structure of the
urothelium that contribute to the symptoms of increased voiding frequency experienced by
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patients with IC/BPS. Overall, the intent of this dissertation is to discover new information
about the pathophysiology of IC/BPS that may then lead to novel therapeutic treatment
targets for patients with this pathology.
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Abstract
High expression of VEGF is associated with immature angiogenesis within the urinary
bladder wall and bladder afferent nerve sensitization, leading to visceral hyperalgesia and
pelvic pain. Research suggests a shift in VEGF alternative splice variant (VEGF-Axxxa and
VEGF-Axxxb) expression with several pathologies (e.g., neuropathic pain and
inflammation) as well as differing effects on pain. Translational studies have also
demonstrated increased total VEGF expression in the bladders of women with interstitial
cystitis/bladder pain syndrome. In the present study, we quantified VEGF alternative splice
variant expression in lower urinary tract tissues under control conditions and with
cyclophosphamide (CYP)-induced cystitis. Using conscious cystometry and intravesical
instillation of a potent and selective VEGF receptor 2 (VEGFR2) tyrosine kinase inhibitor
(Ki8751, 1 mg/kg) in Wistar rats (male and female) with acute and chronic CYP-induced
cystitis and control (no CYP) rats, we further determined the functional effects of VEGFR2
blockade on bladder function. With VEGFR2 blockade, bladder capacity increased
(P≤0.01) in male and female control rats as well as in male and female rats with acute
(P≤0.05) or chronic (P≤0.01 for males and P≤0.05 for females) CYP-induced cystitis. Void
volume also increased in female control rats (P≤0.01) and female rats with acute (P≤0.05)
or chronic (P≤0.05) CYP-induced cystitis as well as in male control rats (P≤0.05) and male
rats with chronic CYP-induced cystitis (P≤0.01). These data suggest that VEGF may be a
biomarker for interstitial cystitis/bladder pain syndrome and that targeting VEGF/VEGFR2
signaling may be an effective treatment.
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Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic pelvic pain
condition with no known etiology. IC/BPS is described by patients as a myriad of
unpleasant sensations, including pain, pressure, and discomfort throughout the pelvic
region. Patients also experience increased urgency and frequency of voiding, without the
presence of infection or other secondary causes (Hanno, Burks et al. 2011). Risk factors
for developing IC/BPS have not been determined, and diagnosis is based on symptoms
followed by an exclusion of other pathologies (Dagher, Curatolo et al. 2017). Neither a
universal biomarker nor an effective treatment has been identified. A clinically relevant
biomarker for IC/BPS could aid in understanding the pathophysiology of the disease,
provide a useful diagnostic tool, and offer a potential treatment target.
In IC/BPS, inflammation causes damage to the mucosal as well as the
glycosaminoglycan layer. The urothelium is a large component of the mucosa, and, upon
inflammation, cytokines and chemokines are recruited to the sites of damage, where mast
cell activation occurs (Grover, Srivastava et al. 2011). Furthermore, the urothelial barrier
becomes leaky, allowing excess cations (e.g., K+) to enter the inner layers of the urinary
bladder. This influx of K+ causes sprouting and sensitization of afferent C-fibers in the
urinary bladder and further increases mast cell recruitment (Parsons, Greenberger et al.
1998, Grover, Srivastava et al. 2011). During this process, research suggests that damaged
urothelial cells release substances (e.g., ATP, nitric oxide, and nerve growth factor) that
further sensitize bladder afferent nerves. In turn, the nerves release neurochemicals locally
in the bladder as well as centrally, creating a vicious, positive, proinflammatory feedback
loop that contributes to hyperalgesia and allodynia (Birder, Apodaca et al. 1998, Burnstock
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2001, Yu and de Groat 2008, Grover, Srivastava et al. 2011, Yoshimura, Oguchi et al.
2014).
VEGF-A (hereafter referred to as VEGF) is a central growth factor underlying pain
associated with the lower urinary tract (LUT). Alternative splicing of VEGF yields two
isoforms, VEGF-Axxxa and VEGF-Axxxb (where “xxx” represents the number of amino
acids in the mature protein; Harper and Bates 2008), which differ only in six COOHterminal amino acids in the mature protein. Previous research by Hulse, et al. (2014) has
suggested an opposing role for the isoforms in models of neuropathic pain. Using
exogenous protein as well as splicing inhibitors to control endogenous splicing in the
environment of peripheral nerve injury, they demonstrated that VEGF-Axxxa increases
pain, whereas VEGF-Axxxb decreases pain severity (Hulse, Beazley-Long et al. 2014).
Both VEGF isoforms primarily signal through two receptors (VEGFR), VEGFR1
and VEGFR2, both of which are receptor tyrosine kinases. However, the downstream
effects of VEGFR2 activation vary between the splice variants since VEGFxxxa is a full
agonist for VEGFR2 and VEGFxxxb lacks the ability to cause efficient autophosphorylation
of the receptor (Harper and Bates 2008, Kawamura, Li et al. 2008, Stevens and Oltean
2018). VEGFR2 is the best-characterized VEGF receptor while the function of VEGFR1
remains more uncertain. VEGFR1 may regulate and dampen VEGF/VEGFR2 signaling in
that it acts as a “decoy” by binding and trapping VEGF (Olsson, Dimberg et al. 2006).
VEGF binding to VEGFR2 typically results in angiogenesis via intracellular
phosphorylation and activation of several downstream signaling cascades that, ultimately,
result in endothelial cell proliferation and blood vessel formation (Kroll and Waltenberger
1997, Chen, Yang et al. 2013). Under normal conditions, angiogenesis is necessary to
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ensure that target tissues receive adequate blood supply. If an organ is hypoxic, target cells
secrete VEGF to promote angiogenesis. VEGF is then downregulated once the target organ
receives an adequate supply of oxygen (Carmeliet 2003, Carmeliet and Tessier-Lavigne
2005). However, in pathological conditions, secretion of VEGF contributes to the
formation of immature blood vessels that subsequently, become leaky and hemorrhagic
(Eberhard, Kahlert et al. 2000, Kiuchi, Tsujimura et al. 2009).
Angiogenic factors, such as VEGF, are associated with, and contribute to, several
neurological conditions (Malykhina, Lei et al. 2012, Vallon, Chang et al. 2014, Shim and
Madsen 2018). As a potent angiogenic factor, VEGF may have additional roles in the
urinary bladder during inflammation. VEGF and its receptors are expressed in urothelial,
lamina propria, and intramural ganglia cells within the bladder wall under normal
conditions. Additionally, under pathological conditions such as inflammation, VEGF
expression is upregulated in these areas (Chun, Lim et al. 2007, Saban, Backer et al. 2008,
Kiuchi, Tsujimura et al. 2009). Furthermore, in the inflamed bladder, VEGF promotes
nerve plasticity. VEGF infusion into mouse urinary bladder increased the number of
sensory fibers expressing transient receptor potential vanilloid subfamily 1, substance P,
and calcitonin gene-related peptide to levels similar to those reported in chronically
inflamed mouse urinary bladder (Saban, Davis et al. 2011). VEGF infusion also caused an
increase in vasodilation, edema, and recruitment of macrophages, all of which are
associated with inflammation. Infusion of a VEGF-neutralizing antibody prevented
inflammation-induced afferent nerve plasticity (Saban, Davis et al. 2011) and attenuated
pelvic sensitivity, as determined by von Frey filament testing (Lai, Shen et al. 2017). The
literature shows conflicting roles of VEGF in frequency of micturition; for example, anti-
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VEGF

treatment

involving

antiVEGF-neutralizing

antibodies

decreased

pelvic

hypersensitivity but failed to affect voiding frequency after cyclophosphamide (CYP)induced cystitis in mice (Lai, Shen et al. 2017). In contrast, 2 weeks of intravesical
instillation of VEGF reduced bladder capacity in mice evaluated with conscious cystometry
(Malykhina, Lei et al. 2012). Furthermore, the urinary bladders of patients with IC/BPS
exhibit increased VEGF, and the levels of VEGF positively correlated to reported pain
severity (Kiuchi, Tsujimura et al. 2009, Lee and Lee 2011). By blocking VEGF/VEGR2
signaling using Ki8751, a potent selective VEGFR2 tyrosine kinase inhibitor, we
hypothesized that functional improvements in micturition, as shown by increased bladder
capacities and void volumes, will occur when this positive feedback loop is interrupted.
We further aimed to examine VEGF splice variants in different lower urinary tract (LUT)
tissues under control and CYP conditions.
Materials and Methods
Experimental animals
These experiments from the Vizzard laboratory were performed in accordance with
institutional and national guidelines and regulations. The University of Vermont
Institutional Animal Care and Use Committee approved all experimental protocols (no. 14060 and no. 13-030) involving animal use. Animal care was under the supervision of
University of Vermont’s Office of Animal Care and Management in accordance with the
Association for the Assessment and Accreditation of Laboratory Animal Care and National
Institutes of Health guidelines. All efforts were made to minimize the potential for animal
pain, stress, or distress. Male and female Wistar rats (n=6-8 male rats and 6-8 female rats
per treatment group) were bred locally at the Larner College of Medicine at the University
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of Vermont. Rats were maintained under standard laboratory conditions: they were housed
two per cage and maintained on a 12:12-h light-dark cycle, with free access to food and
water. Estrous cycle status was not determined in female rats before use.
Tissue collection for mRNA analysis.
Rats were anesthetized with isoflurane (5% in oxygen) and euthanized via
thoracotomy, and spinal cord segments (L6 and S1), dorsal root ganglia (DRG; L6 and S1),
and urinary bladders were harvested from all treatment groups. The urinary bladder was
quickly dissected under RNase-free conditions. The bladder was cut open along the midline
and pinned to a Sylgardcoated dish, and the urothelium, including the suburothelium, was
removed from the detrusor muscle with fine forceps and iris scissors; the urothelium and
detrusor were evaluated separately by mRNA analysis.
Quantification of VEGF splice variant mRNA
Stat-60 total RNA/ mRNA isolation reagent (Tel-Test B Labs, Friendswood, TX)
was used to extract total RNA from samples (n=6). One microgram (bladder and spinal
cord) or 0.1 µg (DRG) of RNA sample was used to synthesize cDNA using a mix of
random hexamers and oligo(dT) primers with Moloney murine leukemia virus reverse
transcriptase (Promega). Primers were designed using Oligo Primer Analysis Software 7.0.
VEGF-Axxxa and VEGF-Axxxb isoform primers were designed against exon 7/8. The
forward primer spans the intron/exon boundary: VEGF forward primer 5=AGCATTTGTTTGTCCAAGATCC-3=. The reverse primers cover the region where the
six

different

amino

acids

are

TCACCGCCTTGGCTTGTCACAT-3=

coded:
and
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VEGF-Axxxa

reverse

primer

5=-

VEGF-Axxxb

reverse

primer

5=-

TTAATCGGTCTTTCCTTTGAGA-3=. The quantitative PCR standard for each transcript
was prepared with the amplified cDNA products ligated directly into the pCR2.1 TOPO
vector using the TOPO TA cloning kit (Invitrogen). The nucleotide sequences of the inserts
were verified by automated fluorescent dideoxy dye terminator sequencing (Vermont
Integrative Genomics Resource). cDNA templates were diluted 10-fold and assayed using
Luna universal quantitative PCR master mix (New England Biolabs). Real-time
quantitative PCR was performed (7500 Fast real-time PCR system, Applied Biosystems,
Foster City, CA) under standard conditions as follows: 1) serial heating at 94°C for 2 min
and 2) amplification over 45 cycles at 94°C for 15 s and 56 – 60°C, depending on primer
sets, for 30 s. The amplified product was subjected to SYBR green I melting analysis by
ramping the temperature of the reaction samples from 60 to 95°C. A single DNA melting
profile was observed under these dissociation assay conditions, demonstrating
amplification of a single unique product free of primer dimers or other anomalous products.
For data analyses, a standard curve was constructed by amplification of serially diluted
plasmids containing the target sequence. Data were analyzed at the termination of each
assay using sequence detection software (version 1.3.1, Applied Biosystems, Norwalk,
CT). In standard assays, default baseline settings were selected. The increase in SYBR
green I fluorescence intensity (ΔRn) was plotted as a function of cycle number, and the
threshold cycle was determined by the software as the amplification cycle at which ΔRn
first intersects the established baseline. Normalized data were expressed first as the relative
quantity of the gene of interest normalized to the relative quantity of the housekeeping gene
L32 or 18S. To standardize presentation of these results, expression of each gene in the
control samples was set at 100, and values for other regions were calculated relative to the
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control. To evaluate the percent expression of VEGFAxxxa and VEGF-Axxxb mRNA
isoforms, data were expressed as the absolute quantity of the gene of interest generated by
the standard curve.
Adult bladder catheter implantation
Male and female Wistar rats (n=6-8 male rats and 6-8 female rats per treatment
group) were anesthetized with isoflurane in oxygen (3-4%). A lower midline abdominal
incision was made, and polyethylene tubing (PE-50, Clay Adams, Parsippany, NJ) with a
flared end was inserted into the bladder dome and secured while the opposite end was
tunneled subcutaneously and externalized at the dorsal neck, as previously described
(Schnegelsberg, Sun et al. 2010, Gonzalez, Peterson et al. 2015). Animals received both
pre- and post-operative analgesics (carprofen, 5 mg/kg) once per day for a total of 2 days
after surgery.
CYP dosing and administration
Rats were anesthetized with isoflurane (2–3%), and acute cystitis was induced with
a single injection of CYP (150 mg/kg i.p.). For cystometry experiments, chronic cystitis
was induced with a total of three injections of CYP (75 mg/kg i.p.), one injection every 72
h, with a final injection 4 h before conscious cystometry on day 7. For mRNA analyses,
chronic cystitis was induced with a total of three injections of CYP (75 mg/kg i.p.), one
injection every 72 h with a final injection 24 h before tissue collection. Rodents were used
in studies either 4 h after treatment (acute, 4 h CYP) or 7-8 d after initial treatment (chronic
CYP). Control rodents received no CYP treatment (Gonzalez, Peterson et al. 2015).
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Ki8751 preparation
Ki8751 (Tocris, Bristol, UK) was infused intravesically at 1 mg/kg (Im, Rhee et al.
2010). For infusion into the bladder on the day of testing, the stock solution of Ki8751
was dissolved in 100% DMSO diluted with saline to a final volume such that DMSO
volume was 6% of the final solution. The solution was then vortexed, sonicated, and drawn
up into a sterile syringe for infusion into the urinary bladder. Vehicle (6% DMSO in sterile
saline), which produced no change in bladder function parameters, was also infused into a
separate cohort of rats (data not shown).
Conscious, open outlet cystometry with continuous infusion and effects of Ki8751,
a potent and selective VEGFR2 antagonist
Conscious cystometry was performed as previously described (Schnegelsberg, Sun
et al. 2010, Gonzalez, Peterson et al. 2015) 3 days (d) after bladder catheter implantation.
An unrestrained rat was placed in a Plexiglas cage with a wire bottom, the bladder was
emptied, and the catheter was connected via a T tube to a pressure transducer (model
PT300, Grass Instruments, West Warwick, RI) and a microinjection pump (model 22,
Harvard Apparatus, South Natick, MA). A small animal cystometry laboratory station
(MED Associates, St. Albans, VT) was used for urodynamic measurements
(Schnegelsberg, Sun et al. 2010, Gonzalez, Peterson et al. 2015), as previously described.
Saline solution was infused at room temperature into the bladder at a rate of 166.7 µl/min
for 20-30 min to acclimate the rat to the saline infusion. After the acclimation period, saline
was continuously infused to elicit at least six reproducible bladder-voiding contractions
(Schnegelsberg, Sun et al. 2010, Gonzalez, Peterson et al. 2015). Ki8751 was then infused
at 1 mg/kg (Im, Rhee et al. 2010) directly into the bladder over a 30 min period.
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Immediately after the Ki8751 infusion, saline solution was infused again as previously
described until at least six more reproducible micturition cycles occurred. The following
functional cystometric parameters were recorded in each animal during continuous
cystometry: minimum pressure (pressure at the beginning of bladder filling), threshold
pressure (bladder pressure immediately before micturition), maximum micturition
pressure, intermicturition interval (time between micturition events), infused volume, void
volume, and presence and amplitude of nonvoiding bladder contractions (NVCs;
Schnegelsberg, Sun et al. 2010, Gonzalez, Peterson et al. 2015). Bladder capacity was
determined functionally (functional bladder capacity) as the volume infused into the
bladder beginning when bladder pressure from the preceding voiding event returned to
baseline and ending when micturition commenced (increase in bladder pressure with
release of urine). Functional bladder capacity will hereafter be referred to as “bladder
capacity” (Gonzalez, Peterson et al. 2015). At the conclusion of the experiment, rats were
euthanized (5% isoflurane in oxygen plus thoracotomy).
Statistical Analyses
Values are means ± SEM. Data were compared using one-way ANOVA as well as
paired or unpaired two-tailed Student’s t-tests as appropriate with GraphPad Prism
statistical software (La Jolla, CA). Differences with P≤0.05 were considered statistically
significant.
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Results
Relative expression of VEGF splice variants depends on LUT tissue type.
In all tissue types examined, we found greater expression of the splice variant
VEGF-Axxxa (90%) than VEGF-Axxxb in control (no CYP) animals (Fig. 2-1).
Interestingly, we found differences in the relative expression of VEGF-Axxxa and VEGFAxxxb depending on the tissue type. In the urothelium, 97.05% of total VEGF was expressed
as VEGF-Axxxa and 2.95% as VEGF-Axxxb. Similarly, in the detrusor, 95.54% of VEGF
was expressed as VEGF-Axxxa and 4.46% as VEGF-Axxxb. In spinal cord levels L6 and S1,
lumbosacral levels that are crucial for micturition, 99.8% of total VEGF was expressed as
VEGF-Axxxa and 0.20% as VEGF-Axxxb in L6 and 99.67% was expressed as VEGF-Axxxa
and 0.33% as VEGF-Axxxb in S1. In DRG L6 and S1, 93.93% of total VEGF was expressed
as VEGF-Axxxa and 6.13% as VEGF-Axxxb in L6 and 91.02% of total VEGF is expressed
as VEGF-Axxxa and 8.98% as VEGF-Axxxb in S1.
Effects of CYP-induced cystitis on VEGF-Axxxa/ VEGF-Axxxb isoform expression.
In the urothelium after acute (4 h) CYP-induced cystitis, VEGF-Axxxa and VEGFAxxxb expression increased (204-243%) significantly relative to control (P≤0.01 and
P≤0.05, respectively). In the urothelium after 48 h and 8 d, VEGF-Axxxa significantly
decreased, nearing control levels (P≤ 0.05), whereas VEGF-Axxxb remained elevated. After
CYP-induced cystitis, no significant changes in VEGF-Axxxa or VEGF-Axxxb expression
occurred in the detrusor at any time (Fig. 2-2, A and B). In the spinal cord, we did not
observe an increase in VEGF-Axxxa in L6. VEGF-Axxxa expression in S1 was increased in
the chronic condition compared with acute (4 h) CYP-induced cystitis (P≤0.05). VEGF-
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Axxxb expression significantly increased 8 d after CYP treatment compared with other time
points examined in spinal cord levels L6 and S1 (P≤0.01 for all time points; Fig. 2-2, C
and D). After chronic (8 d) CYP-induced cystitis, expression of VEGF-Axxxa was
significantly increased (193%) in DRG L6 compared with both the control (P≤0.05) and 4
h (P≤0.05) treatment. Expression of VEGF-Axxxa also increased (145%) in DRG S1 at 48
h (P≤0.05) of cystitis compared with control. VEGF-Axxxb expression increased
significantly in DRG L6 after 48 h of CYP treatment (P≤0.01 for control and P≤0.05 for 4
h) and remained increased at 8 d (P≤0.01) compared with control and 4 h of CYP treatment.
VEGF-Axxxb expression was also significantly (P≤0.05) increased in DRG S1 48 h after
CYP treatment compared with control (Fig. 2-2, E and F).
Blockade of VEGFR2 increases bladder capacity of male and female rats.
Previous studies have shown that acute (4 h) and chronic (7 d) CYP-induced cystitis
decreases bladder capacity and time between voiding events compared with control (no
CYP) treatment (Arms and Vizzard 2011, Dugan, Malley et al. 2014, Wrobel,
Doboszewska et al. 2017). To evaluate the effect of VEGF signaling through VEGFR2 on
bladder dysfunction in animals with CYP-induced cystitis, we infused Ki8751, a VEGFR2
tyrosine kinase inhibitor, directly into the urinary bladder of male and female rats and
observed the effect on various parameters of micturition. With VEGFR2 blockade, bladder
capacity increased 1.3-fold in control (no CYP) female rats (P≤0.01), 1.4-fold (P≤0.05) in
female rats with acute CYP-induced cystitis, and 1.6-fold in female rats with chronic CYPinduced cystitis (P≤0.05; Fig. 2-3A). Infusion of Ki8751 increased bladder capacity 1.4fold in control male rats (P≤0.01), 1.5-fold in male rats with acute CYP-induced cystitis
(P≤0.05), and 2.1-fold in male rats with chronic CYP-induced cystitis (P≤0.01; Fig. 2-3B).
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Instillation of vehicle solution did not affect bladder capacity in control or CYP-treated
animals (data not shown).
Blockade of VEGFR2 increases void volume.
In the same groups of animals, we evaluated void volume by measuring the amount
of infused saline excreted by the rats. In control rats after VEGFR2 blockade, void volume
increased 1.2-fold in female rats (P≤ 0.01) and 1.3-fold in male rats (P≤0.05). In female
rats with acute CYP-induced cystitis, void volume increased 1.3-fold (P≤0.05) after
Ki8751 infusion; however, no change was observed in male rats. In rats with chronic CYPinduced cystitis after VEGFR2 blockade, void volume increased 1.4-fold in female rats
(P≤ 0.05) and 2.2-fold in male rats (P≤0.01; Fig. 2-4). Void volume was unchanged after
infusion of vehicle solution (data not shown).
Blockade of VEGFR2 decreases voiding frequency.
In response to continuous intravesical instillation of saline after Ki8751 infusion
compared with baseline before drug infusion, the intercontraction interval was significantly
increased (voiding frequency decreased) by the following amounts in all groups: 1.3-fold
(P≤0.01) in control female rats, 1.4-fold (P≤0.01) in control male rats, 1.4-fold (P≤0.05)
in female rats with acute CYP-induced cystitis, 1.5-fold (P≤0.01) in male rats with acute
CYP-induced cystitis, 1.6-fold (P≤0.05) in female rats with chronic CYP-induced cystitis,
and 2.2-fold (P≤0.01) in male rats with chronic CYP-induced cystitis (Fig. 2-5, male rat
data not shown). Blockade of VEGF/VEGFR2 signaling with Ki8751 in male rats with
chronic CYP-induced cystitis decreased threshold (P≤0.01), minimum (P≤0.01), and
average (P≤0.05) bladder pressure, although no other changes in bladder pressures were
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observed in any other groups (Table 2-1). Infusion of vehicle solution did not affect
intercontraction interval or bladder pressure in any of the groups. In addition, NVCs were
not consistently observed in either experimental group (control vs. CYP) or sex; therefore,
analyses were not performed.
Discussion
The present study extends our understanding of VEGF splice variant isoform
expression and the functional role of VEGF/VEGFR2 signaling in bladder inflammation
in response to acute (4 h) and chronic (7−8 d) CYP-induced cystitis. In the present study,
we demonstrated tissue-specific distribution of VEGF-Axxxa/VEGF-Axxxb under control
conditions and changes in splice variant expression during various durations of CYPinduced cystitis compared with control. We also showed functional improvements in
micturition by blockade of VEGF/VEGFR2 signaling in rats with CYP-induced cystitis
and control rats. We demonstrated that blockade of VEGFR2 within the urinary bladder
leads to a significant increase in bladder capacity in control and CYP-treated rats of both
sexes. Additionally, we found that void volume increases after infusion of the VEGFR2
antagonist in all groups except for male rats with acute CYP-induced cystitis. The
magnitude of the change in bladder capacity before versus after Ki8751 infusion was
greater in male rats with chronic CYP-induced cystitis than control rats (P≤0.05). Although
there were no significant differences in the magnitude of change between male and female
rats before versus after infusion of the VEGFR2 antagonist, for female rats, the drug effect
was the same for each experimental group (control vs. acute CYP vs. chronic CYP); for
male rats, however, the increase in bladder capacity and void volumes was greatest in the
chronic condition followed by the acute condition and, finally, the control condition. To
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further understand the role of VEGF/VEGFR2 signaling, specifically under inflammatory
conditions, future research could include dose-response studies that may highlight
differences between the effect of Ki8751 on no CYP (control) and CYP conditions. The
present data suggest that blockade of VEGF/VEGFR2 signaling has a greater effect on
male rats with chronic CYP-induced bladder inflammation and highlight the importance of
including both sexes in experimental design.
Although previous studies have quantified VEGF protein expression and reported
a significant proportion of both VEGF isoforms in various tissues (Bevan, van den Akker
et al. 2008, Harper and Bates 2008, Hulse, Beazley-Long et al. 2014), we found that, with
respect to mRNA expression, VEGF-Axxxa predominated over VEGF-Axxxb in all LUT
tissue types examined. The difference in VEGF-Axxxa and VEGF-Axxxb expression
between our findings and those reported in the literature may be due to the differences in
the quantification of mRNA versus protein. Specifically, the difference in mRNA
expression and protein expression of VEGF splice variants suggests posttranslational
modification as a possible mechanism for the increased expression of VEGF-Axxxb in
different tissue types. Alternatively, differences in isoform expression may be due to
variation among different tissue types since the role of splice variant differential expression
remains to be elucidated. Like studies that used a model of neuropathic pain, we used the
CYP-induced cystitis model of bladder inflammation to demonstrate differences in VEGF
splice isoform expression. Our model suggests that both VEGF-Axxxa and VEGF-Axxxb
increase in LUT tissues after CYP-induced cystitis. Specifically, we found that levels of
VEGF-Axxxa and VEGF-Axxxb increase in the urothelium 4 h after CYP. All changes in
VEGF-Axxxa and VEGF-Axxxb in the lumbosacral spinal cord and DRG occurred after
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longer durations (between 48 h and 8 d) of CYP-induced cystitis. This time course may
indicate that the urothelium is the first, local, target of CYP, whereas a shift in mRNA in
the lumbosacral spinal cord and DRG, distal to the initial effects of CYP, may require more
time.
It has previously been shown in our laboratory that, after acute (2–48 h) CYPinduced cystitis, VEGF protein expression increases in the whole bladder as well as in the
urothelium, suburothelial vasculature, and detrusor smooth muscle (Cheppudira, Girard et
al. 2008). Furthermore, the Multidisciplinary Approach to the Study of Chronic Pelvic Pain
Research Network recently showed that urine levels of VEGF are increased in patients with
urological chronic pelvic pain syndrome, which could indicate upregulation of VEGF
signaling in the urinary bladder of these patients (Dagher, Curatolo et al. 2017). However,
the mechanism by which VEGF becomes upregulated during bladder inflammation is
unknown. One hypothesis involves the ischemic environment of the urinary bladder in
patients with IC/BPS. Although basal bladder blood flow is the same in patients with and
without IC/BPS, research has suggested that blood flow during the filling stage of
micturition is significantly different. Specifically, bladder blood perfusion increases in
control individuals during bladder filling but decreases in patients with IC/BPS (Pontari,
Hanno et al. 1999). Since ischemia stimulates angiogenesis, VEGF, as a proangiogenic
factor, may increase in the urinary bladder during this time in individuals with IC/BPS
(Marti and Risau 1999, Pontari, Hanno et al. 1999, Dagher, Curatolo et al. 2017). Another
hypothesis involves the role of VEGF in vascular permeability. Research has determined
that VEGF increases the permeability of blood vessels in several ways, for example, by
disrupting the tight junction barrier of endothelial cells directly by phosphorylating the
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tight junction regulator protein zonula occludens 1 (ZO-1; Antonetti, Barber et al. 1999).
In the urothelium, ZO-1 is one of the tight junction proteins responsible for the barrier
properties of the urothelium that prevent toxic metabolites and ions in the urine from
penetrating into the deeper layers of the walls of the urinary bladder. It is possible that
VEGF in the urine acts on ZO-1 in urothelial cells, thereby increasing urothelial
permeability and increasing the amount of VEGF and other molecules that can access
deeper bladder structures, including bladder vasculature and nerves.
Once VEGF accesses the layers of the urinary bladder, it can have profound effects
on the vasculature by increasing angiogenesis and sensitizing afferent nerve endings.
Mediators of angiogenesis are actively being considered as potential targets for a variety
of chronic inflammatory pathologies. In models of chronic urinary bladder inflammation,
there is evidence supporting a marked increase in the innervation of sensory neurons
expressing transient receptor potential vanilloid subfamily 1 (Charrua, Reguenga et al.
2009), substance P, and calcitonin gene-related peptide (Saban, Davis et al. 2011). This
increase in sensory nerve density has been recapitulated in control mice that receive an
instillation of VEGF into their bladder (Saban, Davis et al. 2011). In this model, functional
bladder changes mirroring the symptoms of IC/BPS (e.g., reduced micturition pressure and
intercontraction interval), along with increased pelvic sensitivity, were seen (Saban, Davis
et al. 2011). These results suggest that VEGF is directly linked to the peripheral nervous
system and may impact the neural control of the bladder under inflammatory conditions.
Blockade of VEGF/VEGR2 signaling in the urinary bladder leads to increased
bladder functional outcomes; however, many questions remain. Future experiments will
include examination of the role of VEGF/VEGFR1 signaling in CYP-induced cystitis,
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since VEGFR1 has also been shown to be involved in angiogenesis and inflammation
(Autiero, Luttun et al. 2003, Huang, Shen et al. 2011, He, Wang et al. 2015). Furthermore,
because both VEGFRs have been shown to be present and functionally active in urothelial
and neuronal cells of both human and animal models of bladder inflammation (Burgu,
Medina Ortiz et al. 2007, Saban, Backer et al. 2008), these receptors are potential targets
for the regulation of angiogenesis in a model of CYP-induced cystitis. To understand the
effect of VEGF on inflammatory mediators, we could examine different proinflammatory
molecules in the bladders of animals with CYP-induced cystitis before and after Ki8751
administration to determine if VEGF signaling plays a direct role in the inflammatory
milieu. von Frey filament testing of pelvic hypersensitivity in rats with CYP-induced
cystitis after VEGFR2 blockade could provide insight into the VEGF/VEGFR2
contribution to bladder dysfunction as well as pelvic pain. In summary, our study
demonstrates that VEGF/VEGFR2 signaling blockade improves bladder function, as
demonstrated by the increase in bladder capacity and void volume in control rats and those
with acute and chronic urinary bladder inflammation.
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Tables and Figures

Figure 2-1. The proportion of total VEGF that is expressed as the VEGF-Axxxa versus VEGFAxxxb isoform is lower urinary tract tissue specific. Although each tissue expressed significantly
more VEGF-Axxxa than VEGF-Axxxb, the highest proportion of VEGF-Axxxa to VEGF-Axxxb
occurred in the urinary bladder and the lumbosacral dorsal root ganglion (DRG), whereas the
lowest occurred in the lumbosacral spinal cord. Values are means ± SEM; n = 6.
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Figure 2-2. A and B: expression of VEGF-Axxxa and VEGF-Axxxb isoforms increased in the
urothelium (Uro) of rats with acute (4 h) cyclophosphamide (CYP)-induced cystitis (P≤0.01
and P≤0.05, respectively), returned to control levels after 48 h (P≤0.05), and remained at control
levels after 8 d (P≤0.01). C and D: expression of VEGF-Axxxa was significantly greater at spinal
cord (SC) level S1 after chronic CYP treatment than after 4 and 48 h of CYP treatment (P≤0.05).
Expression of VEGF-Axxxb was significantly greater at spinal cord levels L6 and S1 after 8 d
of CYP treatment than all other time points (P≤0.01). E and F: in dorsal root ganglion (DRG)
L6, VEGF-Axxxa and VEGF-Axxxb were upregulated after 8 d of CYP treatment compared with
control levels and 4 h of CYP treatment (P≤0.05 and P≤0.01, respectively). VEGF-Axxxb was
significantly increased 48 h after CYP treatment compared with control (P≤0.01) and 4 h after
CYP treatment (P≤0.05). In DRG S1, VEGF-Axxxa and VEGF-Axxxb were upregulated
significantly 48 h after CYP treatment compared with control levels (P≤0.05). Values are
means±SEM; n = 6. Statistical analyses were performed on raw data before transformation.
*P≤0.05; **P≤0.01.

Figure 2-3. Bladder capacity was significantly increased in both male and female control rats
(n=8 female rats and n=6 male rats), rats with acute (4 h) cyclophosphamide (CYP)-induced
cystitis (n=8 female rats and n=6 male rats), and rats with chronic CYP-induced cystitis (n=6
female rats and n=6 male rats). After VEGF/VEGF receptor 2 (VEGFR2) signaling blockade
with Ki8751, bladder capacities significantly increased in female control rats (P≤0.01) and
female rats with acute (P≤0.05) and chronic (P≤0.05) CYP-induced cystitis (A) as well as in
male control rats (P≤0.01) and male rats with acute (P≤0.05) and chronic (P≤0.01) CYPinduced cystitis (B). Values are means ± SEM. *P≤0.05; **P≤0.01.

91

Figure 2-4. Void volume was significantly increased in female and male control rats, male and
female rats with chronic cyclophosphamide (CYP)-induced cystitis, and female rats with acute
(4 h) CYP-induced cystitis (n=6–8). After VEGF/VEGF receptor 2 (VEGFR2) signaling
blockade with Ki8751, void volume significantly increased in control female rats (P≤0.01) and
female rats with acute (P≤0.05) and chronic (P≤0.05) CYP-induced cystitis as well as in control
male rats (P≤0.05) and male rats with chronic CYP-induced cystitis (P≤0.01). Values are means
± SEM. *P≤0.05, **P≤0.01. ns, not significant.
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Figure 2-5. Representative cystometry traces from female control rats (A) and female rats with
acute (B) and chronic (C) cyclophosphamide (CYP)-induced cystitis before and after infusion
of Ki8751 into the urinary bladder (n=6–8). Traces show increased intercontraction intervals
after infusion of the VEGF receptor 2 (VEGFR2) antagonist Ki8751 in all groups. Additionally,
there was no difference in amplitude or number of nonvoiding bladder contractions in control
rats or rats with CYP-induced cystitis.

Table 2-1. Mean bladder pressures during open-outlet, conscious cystometry before and
after Ki8751 infusion in no CYP control, acute CYP, and chronic CYP male and female
rats.
Minimum
Pressure
(cm H2O)

Average
Pressure
(cm H2O)

Maximum
Pressure
(cm H2O)

Control Pre-infusion
Control Post-infusion

Threshold
Pressure
(cm H2O)
Female
13.2 ± 0.9
14.1 ± 0.9

10.2 ± 0.8
8.4 ± 0.3

13.1 ± 1.3
12.0 ± 0.5

35.5 ± 3.8
36.5 ± 3.6

4h CYP Pre-infusion
4h CYP Post-infusion

21.0 ± 3.7
18.6 ± 3.1

16.7 ± 3.0
14.4 ± 2.5

19.0 ± 3.2
16.6 ± 2.7

43.9 ± 5.9
41.0 ± 6.2

Chronic CYP Pre-infusion
37.4 ± 7.2
Chronic CYP Post-infusion 36.8 ± 5.0
Male
Control Pre-infusion
12.8 ± 1.1
Control Post-infusion
12.6 ± 0.9

25.6 ± 6.2
22.5 ± 3.9

30.2 ± 6.7
28.1 ± 4.7

71.5 ± 9.7
73.5 ± 6.7

9.0 ± 0.8
8.3 ± 1.0

11.4 ±1.1
10.5 ± 1.0

40.9 ± 3.6
35.3 ± 3.7

4h CYP Pre-infusion
4h CYP Post-infusion

16.3 ± 0.3
16.2 ± 1.0

12.6 ± 0.4
11.3 ± 0.5

14.3 ± .4
13.9 ± 0.6

41.2 ± 2.1
40.0 ± 2.3

Chronic CYP Pre-infusion
Chronic CYP Post-infusion

32.3 ± 2.5
22.7 ± 1.1**

23.0 ± 2.2
13.6 ± 1.1**

26.6 ± 2.3
16.3 ± 1.3*

61.8 ± 3.4
52.7 ± 4.2

Values are means ± SEM; n=6–8 rats/group. CYP, cyclophosphamide. A paired, two-tailed
Student’s t-test was used to compare urinary bladder pressure parameters before versus after
infusion of Ki8751. Significant difference between before and after Ki8751 infusion: *P ≤ 0.05 and
**P ≤ 0.01.
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Abstract
In the urinary bladder, mechanosensitive channels (MSCs) underlie the transduction of
bladder stretch into sensory signals that are relayed to the PNS and CNS. Piezo1 is a
recently identified MSC that is Ca2+ permeable and is widely expressed throughout the
lower urinary tract. Recent research indicates that Piezo1 is activated by mechanical stretch
or by pharmacological agonism via Yoda1. Aberrant activation of Piezo1 has been
suggested to play a role in clinical bladder pathologies like partial bladder outlet
obstruction and interstitial cystitis/bladder pain syndrome (IC/BPS). In the present study,
we show that intravesical instillation of Yoda1 in female Wistar rats leads to increased
voiding frequency for up to 16 hours after administration compared to vehicle treatment.
In a cyclophosphamide (CYP) model of cystitis, we found that the gene expression of
several candidate MSCs (TRPV1, TRPV4, Piezo1, and Piezo2) were all upregulated in the
urothelium and detrusor following chronic CYP-induced cystitis, but not acute CYPinduced cystitis. Functionally with this model, we show that Ca2+ output is increased
following Piezo1 activation via Yoda1 in acute and intermediate CYP treatment, but not in
naïve (no CYP) nor chronic CYP treatment. Lastly, we show that activation of Piezo1 may
contribute to pathological bladder dysfunction by increasing urothelial permeability
through the downregulation of several tight junction genes including claudin-1, claudin-8,
and zona occludens-1. Together, these data suggest that Piezo1 activation plays a role in
dysfunctional voiding behavior and may be a future, clinical target for the treatment of
pathologies like IC/BPS.
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New and Noteworthy
The contribution of Piezo1 activation to mechanotransduction in the urinary
bladder is not well understood. Utilizing in vivo and ex vivo techniques, the studies in this
manuscript show functional and molecular changes in the urinary bladder of rodents upon
Piezo1 activation with its agonist, Yoda1. Our results indicate a basic mechanistic
understanding of Piezo1 expression and function in the urinary bladder of rodents in normal
and pathological conditions.
Introduction
Proper micturition requires the urinary bladder to act as a reservoir for storage, and
a pump for the elimination of urine. This process relies on the presence of stretch activated
channels (SACs), also known as mechanosensitive ion channels (MSCs), to transduce the
mechanical distention of the bladder wall during accommodation of urine into sensory
signals that are relayed to the central nervous system to perceive bladder fullness.
Several MSCs, like TRPV1 and TRPV4, are expressed in the urothelial cell layer
of the urinary bladder wall and are crucial for the ultimate sensory detection of bladder
distention (Birder, Nakamura et al. 2002, Gevaert, Vriens et al. 2007). Upon stretchinduced activation, these channels open a non-selective cationic pore to allow the influx of
ions, including calcium (Ca2+), into the urothelial cell (Kullmann, Shah et al. 2009,
Mochizuki, Sokabe et al. 2009, Du, Li et al. 2020). This influx of Ca2+ leads to a release of
several neuromodulators, including ATP, which then bind to receptors on afferent nerve
terminals in the deeper layers of the bladder wall. Evidence of this comes from studies that
show the addition of TRPV1 and TRPV4 agonists onto urothelial cells increases ATP
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release from these cells, while the addition of antagonists decreases ATP release (Birder,
Nakamura et al. 2002, Birder, Kullmann et al. 2007, Mochizuki, Sokabe et al. 2009, Girard,
Campbell et al. 2019). This decrease in ATP release following antagonist application is
mirrored by impaired stretch evoked responses in bladders from TRPV1−/− and TRPV4−/−
mice along with low-amplitude bladder activity resulting in increased bladder capacity
(Birder, Nakamura et al. 2002, Gevaert, Vriens et al. 2007). Though this mechanism of
mechanotransduction is well established in TRP channels, over the last decade, a novel
MSC was identified in the urinary bladder called Piezo1.
Piezo1 belongs to a family of Ca2+ permeable ion channels that also includes
Piezo2. Both Piezo1 and Piezo2 are large, mechanically gated ion channels that were
discovered in the Neuro2A mouse cell line in 2010. Since their discovery, numerous
research studies have sought to understand the contribution of these channels to
physiological stimuli like touch, pressure, and stretch (Coste, Mathur et al. 2010). Though
Piezo1 and Piezo2 share ~50% identity, they are functionally distinct and are differentially
expressed in tissues throughout the body. For example, Piezo1 is found in high levels in
the skin, kidneys, lungs, and urinary bladder, while Piezo2 is predominantly expressed in
sensory neurons in the trigeminal ganglia, dorsal root ganglia (DRG), and Merkel cells, as
well as in lower levels in the lungs and urinary bladder (Coste, Mathur et al. 2010).
The present studies primarily focus on Piezo1 due to its expression profile in the
urinary bladder as well as its ability to be pharmacologically manipulated by a
commercially available agonist (Yoda1; Syeda, Xu et al. 2015, Romac, Shahid et al. 2018,
Wang, Chi et al. 2018, Botello-Smith, Jiang et al. 2019). Previous studies have already
shown Piezo1 gene expression throughout all three layers of the bladder wall (urothelium,
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lamina propria, and detrusor; Dalghi, Clayton et al. 2019). Other studies have found similar
results, however, by co-staining with cytokeratin-7, some have observed that Piezo1 gene
and protein expression is predominant in cells of the urothelium (Miyamoto, Mochizuki et
al. 2014). Like other MSCs in the urothelium, upon stretch, activation of Piezo1 leads to
an increase in intracellular calcium concentration ([Ca2+]i) which results in ATP release. In
support of this, in cultured urothelial cells, mechanical stretch stimulation leads to an
increase in [Ca2+]i and release of ATP that was significantly decreased in cells treated with
siRNA against Piezo1 or the non-selective MSC inhibitor, GsMTx4 (Miyamoto,
Mochizuki et al. 2014).
In addition to their role in bladder function, Piezo1 and other MSCs have been
shown to contribute to bladder dysfunction in models of interstitial cystitis/bladder pain
syndrome (IC/BPS; Wang, Wang et al. 2008, Everaerts, Zhen et al. 2010, Dornelles,
Andrade et al. 2014, Liu, Sun et al. 2018, Girard, Campbell et al. 2019). IC/BPS affects as
many as 3.5-8.6 million women and 2.4-5.3 million men in the United States (Berry, Elliott
et al. 2011, Suskind, Berry et al. 2013) and is characterized by the hallmark symptoms of
increased urinary urgency and frequency accompanied by pelvic pain, which typically
presents as increased hyperalgesia and/or allodynia (Meijlink 2014, Reynolds,
Dmochowski et al. 2016). Currently, the etiology is unknown and there are few options for
treatment for patients with this pathology.
In this paper, we show a functional role for Piezo1 activation on micturition in
female rats using an in vivo intravesical instillation of Yoda1 (0.4mg/kg). Further, we show
that MSC mRNA expression, including Piezo1, increases in the urothelium and detrusor
bladder wall layers with differing durations of CYP-induced cystitis. Additionally, short
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exposures to CYP increased urothelial Ca2+ activity following activation of Piezo1. Lastly,
we hypothesize that increased activation of urothelial Piezo1 and subsequent downstream
signaling may contribute to the bladder overactivity symptoms of CYP-induced cystitis
specifically by altering expression of tight-junctions and increasing the permeability of the
urothelium.
Materials and Methods
Experimental animals
The following experiments were performed in accordance with institutional and
national guidelines and regulations. The University of Vermont Institutional Animal Care
and Use Committee approved all experimental protocols (no. X9-020) involving animal
use. Animal care was under the supervision of the University of Vermont’s Office of
Animal Care and Management in accordance with the Association for the Assessment and
Accreditation of Laboratory Animal Care and National Institutes of Health guidelines. All
efforts were made to minimize the potential for animal pain, stress, or distress.
Female Wistar rats (n=5-9 per treatment group, unless otherwise noted) and female
C57/BL6 mice (n=5-6 per treatment group) were bred locally at the Larner College of
Medicine at the University of Vermont or purchased from Charles River Laboratories.
Females were used as subjects due to experiments involving drug administration via
external urethral catheterization. Rats and mice were maintained under standard laboratory
conditions: they were housed two per cage and maintained on a 12:12-h light-dark cycle,
with free access to food and water. Estrous cycle status was not determined before use.
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Yoda1 infusion into the urinary bladder using external catheterization
Rats were anesthetized with isoflurane (2-3%) and externally catheterized using a
transurethral catheter. This was performed using a lubricated 22-gauge gavage needle and
gently inserting it through the urethra and into the bladder, such that it did not have contact
with the bladder wall. Yoda1 (0.4 mg/kg) was infused into the bladder and remained there
for 30 minutes (Liu, Sun et al. 2018, Romac, Shahid et al. 2018, Wang, Chi et al. 2018,
Swain, Romac et al. 2020). A vehicle solution of 5% DMSO in 95% saline was also infused
in a separate cohort of rats. After the 30-minute infusion, the bladder was manually voided.
The rats recovered from anesthesia for 30 minutes before being put into the Urovoid system
to study functional bladder outcomes.
Natural voiding assay using the Urovoid system
Metabolic cages and the Urovoid system (Med Associates, St. Albans Vermont)
were used to study functional voiding parameters in rats. On the day of functional testing,
rats (n=6-7 per group) were placed into individual metabolic cages, situated above a flask
on a balance, connected to a computer with Urovoid software. Rats remained in these cages
with ad libitum access to food and water for 24 h. Over that time, their urine was caught in
a flask on a balance, and the computer recorded the time and weight of each void to obtain
functional voiding parameters such as number of voids, intermicturition interval (the time
between each void to determine voiding frequency) and the mass of each void. Volume of
water consumed by each rat in 24 h was also recorded and analyzed.
Rats received two voiding assessments using the Urovoid system. First, a baseline
assessment was done 7-10 day (d) before Yoda1/vehicle infusion to assess each rat’s
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normal voiding function. Before the start of this baseline Urovoid assessment, the rats were
anesthetized with isoflurane (2-3%), externally catheterized and infused with saline for 30
minutes. For the second assessment, 7-10 d later at the same time, the same rats were
intravesically infused for 30 minutes with Yoda1 (0.4mg/kg) or vehicle while the rats were
anesthetized (2-3% isoflurane). The voiding assessment began 30 minutes after the
infusion. By using this method of repeated assessments, individual differences and
variability were minimized since rats are compared to their own baseline voiding function.
Furthermore, since baseline assessments were done after administration of anesthesia and
a transurethral catheter, the effects seen in the experimental groups are not due to these
variables. Rats were excluded if their volume of water intake in the second (i.e.,
experimental) assessment was increased by over 20% compared to baseline consumption.
CYP administration and tissue harvest
Rats/mice were lightly anesthetized with isoflurane (2–3%) and given a single
injection of CYP (150 mg/kg, i.p. for rats; 200 mg/kg, i.p. for mice) to induce acute and
intermediate cystitis, or three injections (75 mg/kg, i.p. for rats and mice) every 72 h to
induce chronic cystitis. For acute experiments, a cohort of rats/mice were euthanized (5%
isoflurane and thoracotomy) 4 h after the CYP injection. For the intermediate experiments,
rats/mice were euthanized 24 h after the CYP injection. Lastly, for the chronic CYP-treated
cohort, rats/mice were euthanized 24 h after the last CYP injection on day 8. The urinary
bladder was immediately dissected after euthanasia.
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Tissue dissection for mRNA analysis
Following the tissue harvest, the urinary bladder was quickly dissected under
RNase-free conditions. The bladder was cut open along the midline and pinned to a
Sylgard-coated dish, and the urothelium, including the suburothelium, was removed from
the detrusor muscle with fine forceps and iris scissors. The urothelium and detrusor were
evaluated separately.
RT-qPCR for quantitative analysis of gene expression:
We first extracted total RNA from samples (n=5-9) using Stat-60 total RNA/mRNA
isolation reagent (Tel-Test B Labs, Friendswood, TX). RNA samples (2µg) were then used
to synthesize cDNA using a mixture of random hexamers and oligo(dT) primers with MMLV reverse transcriptase (Promega). Primers (Table 3-1) were designed using Oligo
Primer Analysis Software 7.0. We prepared the quantitative PCR standard for each
transcript using the amplified cDNA products ligated directly into the pCR2.1 TOPO
vector using the TOPO TA cloning kit (Invitrogen). To verify the nucleotide sequences of
the inserts, we used automated fluorescent dideoxy dye terminator sequencing (Vermont
Integrative Genomics Resource). All cDNA templates were diluted 10-fold (to limit the
inhibitory effects of the reaction components) and assayed using Luna universal
quantitative PCR master mix (New England Biolabs). We performed qPCR (7500 Fast
real-time PCR system, Applied Biosystems, Foster City, CA) under standard conditions as
outlined: 1) serial heating at 94°C for 2 min and 2) amplification over 45 cycles at 94°C
for 15 s and 60°C for 30 s. The amplified product was exposed to SYBR green I melting
analysis by ramping the temperature of the reaction samples from 60°C to 95°C. We
ensured the creation of a single DNA melting profile under the outlined dissociation assay
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conditions to confirm the amplification of a unique, single product that was free of primer
dimers and other anomalous products.
Quantification of mechanoreceptor and tight junction mRNA expression
For data analysis, we constructed a standard curve by amplification of serially
diluted plasmids containing the target sequence. The data were analyzed at the termination
of each assay utilizing sequence detection software (version 1.3.1, Applied Biosystems,
Norwalk, CT). In standard assays, default baseline settings were selected and the increase
in SYBR green I fluorescence intensity (ΔRn) was plotted as a function of cycle number.
The threshold cycle was determined by the software as the amplification cycle at which
ΔRn first intersects the established baseline. Normalized data are expressed as the relative
quantity of the gene of interest normalized to the relative quantity of the housekeeping gene
L32 or an average of 18S and L32 housekeeping genes.
Preparation of intact urothelial sheets and measurement of intracellular Ca2+
events
Mice were used for Ca2+ imaging experiments due to difficulties loading Ca2+
fluorescent dye into urothelial sheets procured from rats.
Harvested bladders from naïve (no CYP)/4 h/24 h/chronic (8 d) CYP-treated mice
were placed in cold HEPES solution composed of (mM): 134 NaCl, 6 KCI, 10 glucose, 10
HEPES, 1 MgCl2, 2 CaCl2, 10 glucose and adjusted to pH 7.4 with NaOH. The bladder
was cut open along the midline and pinned to a Sylgard coated dish where the urothelium
was separated from the suburothelium (ie: lamina propria) and the detrusor using fine
forceps and iris scissors (Guo, Chang et al. 2018). To detect Ca2+ events, the urothelial
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sheets were loaded with a Ca2+ sensitive fluorescent dye (10 µM Cal 520; AAT Bioquest,
Inc.) for 90 minutes at 37°C before being placed in a physiological saline solution (PSS)
composed of (mM): 119 NaCI, 4.7 KCI, 24 NaHCO3, 1.2 KH2PO4, 2.5 CaCl2, 1.2 MgSO4,
7 glucose and constantly bubbled with Biological Gas (95% O2, 5% CO2) to maintain pH
at 7.4.
To measure Ca2+ activity following Piezo1 activation, the urothelial sheets were
first imaged for 90 seconds to establish baseline Ca2+ activity. The urothelium was then
superfused for 10 minutes with Yoda1 (20 µM) followed by a 90 second recording of the
same region. Changes in Ca2+ activity after Piezo1 activation were then compared to
baseline Ca2+ activity. Vehicle controls (DMSO 0.1%) were also conducted in a separate
cohort of mice (no CYP) to control for laser damage and any cellular effects of DMSO.
Images were collected at a rate of 16 images/second using a Noran Oz laser scanning
confocal microscope (Heppner, Hennig et al. 2017) and a Nikon 60x water immersion
fluorescent objective (NA 1.2). Cal 520 was excited at 488 nm and the emitted fluorescence
was collected at >500 nm (Heppner, Hennig et al. 2017). Analysis of Ca2+ events was
performed with custom-written software (Volumetry G9: Grant Hennig).
Analysis and quantification of Ca2+ events
Image sequences of the urothelium were captured (512x512 at a spatial resolution
0.689µm per pixel and temporal resolution of 0.625 s). The files were saved as multislice
TIFF files and imported into custom-written software (Volumetry G9d, GWH). Motion
stabilization and background intensity normalization (debleaching) was applied as
necessary followed by temporal averaging (±2 frames: total time 3.13s) and spatial
smoothing (Gauss 5x5 pixel, sd=1.0) to reduce noise.
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Loading of Cal520 into the urothelium is often uneven with cells displaying bright
and dim baseline fluorescence intensities. This creates issues when measuring Ca2+ event
amplitudes using the traditional F/F0 ratio, as cells with high background intensities will
have smaller calculated amplitudes compared to cells with low background intensities,
even though the absolute change in intensity during Ca2+ events may be similar.
To circumvent this limitation, we calculated Ca2+ event amplitude using a signalto-noise approach where changes in intensity during Ca2+ events are put in relation to the
variation of intensity during quiescent periods (Longden, Mughal et al. in press). The use
of spatio temporal (ST) maps calculated from active sites is used descriptively in this study
to demonstrate patterns of Ca2+ events but was not used quantitatively due to the ovoid
nature of urothelial cells that was not suited to dimensional averaging. To better measure
the extent and intensity of Ca2+ events in ovoid cells, pixel binning (10 x 10 pixel average)
was used to spatially reduce noise, then a conservative quiescence estimator (20% of the
15m:40s recording time = ~3 mins) was used to demarcate time periods in which a cell was
not active. A histogram of the intensities throughout the recording at each pixel was
calculated, and then the standard deviation (SD) of the dimmest 20% of pixels was
calculated (SDqmin). Quiescent periods were defined statistically as those portions of the
recording that had intensities less than 11.0 SDqmin. Then, within the defined quiescent
periods, standard deviation and average intensity (AVGq) was recalculated (SDq) enabling
the movie intensities to be converted to Z-scores (Zscr: (intensity-AVGq)/SDq). A
threshold was used to define active Ca2+ events (≥2.7 Zscrs) and remaining noise was
filtered using a particle filter (≤3 pixels).
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Contiguous pixels in Ca2+ events were coalesced into coordinate-based particles in
each frame, then an overlap function was used between successive frames to determine the
time course of Ca2+ events and create ST objects. All spatial, temporal, and intensity
information was extracted from Ca2+ event ST objects including duration (s), area (µm2),
maximum intensity (Zscr) and an integrated measure of elevated overall active Ca2+
presence or “output” in the cytoplasm of all cells in the field of view (FOV) we abbreviated
to Zum2s (Zscr • µm2 • s.min-1). This measure multiplied number of active pixels by their
size (µm2), their intensity (Zscr) and their duration (s). This value was normalized to per
minute and is a useful way to summarize changes in Ca2+ activity in the entire FOV.
Statistical analyses
Values are presented as means ± SEM. Power and sample size were determined
using G*Power statistical software. Data were compared using One-Way ANOVA, mixed
model repeated measures ANOVA, and Student’s paired t-test, as appropriate, with SAS
and GraphPad Prism statistical software. For the mixed model repeated measures ANOVA,
statistical test assumptions were not met, therefore, a square root transformation was used
to compress variance in the analysis of the number voiding events, and a natural log
transformation was used on the raw data in the analysis of intermicturition interval and
void mass. Differences with P ≤ 0.05 are considered statistically significant.
Results
Activation of Piezo1 with Yoda1 increases frequency of bladder voiding.
Previous studies in unconscious rats have shown that blockade of Piezo1 using the
non-selective MSC antagonist, GsMTx4 (2.5 µM), increases the intermicturition interval
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(i.e.: the time between voiding events) when infused directly into the bladders of naïve rats,
and rats chronically treated with CYP (Liu, Sun et al. 2018). Thus, we hypothesized that
activating Piezo1 via intravesical infusion of Yoda1 directly into the bladder would
recapitulate the hallmark symptom of increased voiding frequency commonly seen in
patients with IC/BPS and animal models using CYP-treatment.
Changes in voiding parameters after Yoda1 (n=6) were compared to changes after
vehicle (n=7) by testing the group*condition interaction at each timepoint to evaluate the
difference between the effects at each timepoint. Significant differences that are noted
indicate a significant difference between the effects (baseline vs. vehicle compared to
baseline vs. Yoda1 at each timepoint). 0-4 h after baseline infusion, rats voided an average
of 3 times, which significantly increased to an average of 5 times after Yoda1 infusion (P
≤ 0.05; Fig. 3-1A). From 4-8 h after Yoda1 infusion, voiding events increased to an average
of 9 compared to 5 voids at baseline (P ≤ 0.05). From 8-12 h and 12-16 h after Yoda1
infusion, rats voided an average of 9 and 8 times which were significantly more than their
baseline voiding levels during each respective time period (P ≤ 0.05).
These changes in voiding frequency after infusion of Yoda1 corresponded with
decreases in the IMI compared to vehicle such that 0-4 h after Yoda1 infusion, the IMI
decreased from baseline by 50.6% (P ≤ 0.01). From 4-8 h the IMI decreased 45.7% (P ≤
0.001), from 8-12 h the IMI decreased 34.5% (P ≤ 0.01), and from 12-16 h, the IMI
decreased 44.2% compared to baseline (P ≤ 0.01; Fig 3-1B). There were no significant
changes in the number of voiding events or IMI compared to baseline 16-20 h or 20-24 h
after Yoda1 infusion. Interestingly, even with the increase in voiding frequency, there was
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no statistical difference in void mass from baseline after Yoda1 administration compared
to vehicle at any timepoint tested (Fig. 3-1C).
Mechanoreceptor gene expression is increased in the urothelium and detrusor following
chronic, but not acute, CYP-treatment.
Due to the established importance of urothelial signaling in mechanotransduction
and subsequent afferent nerve terminal activation, we hypothesized that there would be
bladder tissue-specific regulation of MSC mRNA during varying durations of CYPinduced cystitis in the urothelium vs. the detrusor. Contrary to this, we observed similar
regulation of all MSCs tested (TRPV1, TRPV4, Piezo1, and Piezo2) in both the urothelium
(Fig. 3-2A-D) and the detrusor (Fig. 3-2E-H). Specifically, we found that compared to
naïve (no CYP-treatment), chronic CYP-treatment led to increases in the mRNA
expression of all MSCs examined: TRPV1 (P ≤ 0.0001), TRPV4 (P ≤ 0.01), Piezo1 (P ≤
0.05), and Piezo2 (P ≤ 0.01) in the urothelium. Similarly, in the detrusor after chronic CYPinduced cystitis, mRNA expression of TRPV1 (P ≤ 0.01), TRPV4 (P ≤ 0.01), Piezo1 (P ≤
0.05), and Piezo2 (P ≤ 0.001), were all upregulated. Additionally, after 24 h of CYP
treatment, TRPV1 and TRPV4 gene expression was increased in the urothelium (P ≤ 0.01
and P ≤ 0.05, respectively) and TRPV4 mRNA was upregulated in the detrusor (P ≤ 0.05).
No changes in MSC expression were observed in acute (4 h) CYP treatment in the
urothelium or the detrusor.
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Activation of Piezo1 with Yoda1 leads to a CYP-dependent increase in Ca2+activity in
urothelial cells.
Given the changes in MSC gene expression, we utilized Ca2+ imaging to determine
CYP-induced functional changes in Piezo1 activity. To ensure any observed effect of
Yoda1 was due to the drug itself, we first tested whether the drug vehicle (0.1% DMSO)
or time affected Ca2+ activity. There was no change in overall Ca2+ activity compared to
baseline after a 10-minute incubation period in the vehicle solution (Fig. 3-3A). In our
experimental groups, we found that Yoda1 elicited differences in urothelial cell Ca2+
activity dependent on duration of CYP-treatment. In urothelial sheets from mice not treated
with CYP, we found no significant difference (P=0.06) in Ca2+ activity after Yoda1
administration (Fig 3-3B).
In urothelial sheets from mice that were treated with acute (4 h; Fig. 3-3C) and
intermediate (24 h; Fig. 3-3D) durations of CYP, we found significant increases in Ca2+
activity compared to baseline after Yoda1 treatment. Specifically, in the 4 h CYP treatment
group, the Ca2+ activity increased by 1.54x106 Zum2s, which represents a 2.67-fold
increase compared to baseline (P ≤ 0.05). Similarly, in the 24 h CYP treatment group, the
Ca2+ activity increased by 7.02x105 Zum2s, a 1.5-fold increase from baseline (P ≤ 0.05).
We observed noticeable within-group variability in the Ca2+ activity of the chronic CYPtreated group and ultimately, there was no difference between Ca2+ activity at baseline and
after Yoda1 in that group (Fig. 3-3E).
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Intravesical Yoda1 infusion leads to reduced expression of tight-junction genes in the
urothelium.
Since there were no significant changes in Ca2+ activity after Yoda1 in the naïve
(no CYP) group, and yet we saw functional voiding changes after intravesical infusion of
Yoda1 in vivo, we wanted to investigate other possible molecular changes following Piezo1
activation with Yoda1. Previous research suggests a relationship between urothelial stretch,
like with distention, and tight junction dynamics (Carattino, Prakasam et al. 2013, Jiang,
Song et al. 2021). Therefore, we hypothesized that activation of Piezo1 may be disrupting
tight junction organization or expression in the urothelium. In this experiment we
investigated gene expression changes in tight junctions that have previously been shown
to be expressed in the urothelium (zona occludens-1 and claudin-2, -4, and -8; Acharya,
Beckel et al. 2004), as well as claudin-1 which has recently been shown to be regulated by
Piezo1 in the intestinal epithelium (Jiang, Song et al. 2021).
Compared to rats treated with vehicle, rats treated with Yoda1 showed significant
decreases in the expression of claudin-1 (Cldn1), Cldn8, and zona occludens-1 (ZO-1)
mRNA in the urothelium (Fig 3-4). Specifically, Cldn1 decreased by 43.6% (P ≤ 0.05),
Cldn8 decreased by 48.2% (P ≤ 0.01), and ZO-1 decreased by 45.0% (P ≤ 0.0001). Gene
expression of Cldn2 and Cldn4 were statistically unregulated by Piezo1 activation when
compared to vehicle.
Discussion
The present study underscores the contribution of Piezo1 in urinary bladder
function and dysfunction. In naïve (no CYP) rats, local pharmacological activation of
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Piezo1 with Yoda1 (0.4 mg/kg) induces changes in natural voiding function that persist for
up to 16 h post administration. Specifically, we show that infusing Yoda1 into the bladder
via non-invasive, external catheterization leads to statistically significant increases in
voiding frequency and decreases in intermicturition interval (IMI) at several time points
compared to baseline voiding parameters (Fig. 3-1). We then assessed regulation of MSC
gene expression in rat bladder (urothelium and detrusor) with CYP-induced cystitis, an
animal model of IC/BPS and a common cause of bladder dysfunction. We found that
several MSC genes including TRPV1, TRPV4, Piezo1, and Piezo2 were all upregulated in
both layers of the bladder (urothelium and detrusor), following chronic CYP-induced
cystitis, but not acute CYP-induced cystitis (Fig. 3-2). To determine functional relevance
of the changes in gene expression of Piezo1, we used Ca2+ imaging to examine differences
in Ca2+ activity with Piezo1 activation in rodents with different durations of CYP treatment.
We found increased Ca2+ activity following addition of Yoda1 (20 µM) in acute (4 h) CYP
treatment and intermediate (24 h) CYP treatment, but not in naïve nor chronic CYPtreatment (Fig. 3-3). Lastly, we found that local activation of Piezo1 led to the
downregulation of several tight junction genes like Cldn1, Cldn8, and ZO-1 (Fig. 3-4).
Together, these data add to our understanding of urinary bladder mechanotransduction and
suggest a potential contribution of Piezo1 activation in pathological bladder function, like
IC/BPS.
To minimize the effects of inflammation on bladder function, we utilized a natural
voiding assay (Urovoid), as opposed to other, more invasive, methods to functionally study
Piezo1. Our functional studies show increases in voiding frequency in conscious, freely
moving rats, over a 24 h period (Fig. 3-1). Specifically, our data suggest these effects
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persist up to 16 h post-infusion of Yoda1. The return of voiding frequency to baseline may
be due to the local effects of Yoda1 wearing off. Alternatively, this attenuation may be due
to the diurnal voiding cycle, since 16-24 h after Yoda1 infusion occurs during the daytime
when rats are typically sleeping. Future studies could lengthen the experimental timeframe
to specifically determine any diurnal effects and if changes in functional voiding occur
long term. Following Yoda1 administration, we show an increase in voiding frequency
compared to vehicle, though we do not see a change in voided volume during the same
time intervals (Fig 3-1C). Because we excluded rats that drank significantly more water
over the 24 h measurement period following Yoda1/vehicle administration, we can exclude
polydipsia as an underlying factor. However, we are uncertain at this time whether the
unchanged void volume is due to technical limitations of metabolic cages and measuring
small voids, or a potential alteration in systemic fluid balance. Future work could use other
voiding assays (e.g. cystometry) and/or peripheral nerve recordings, to determine with
certainty that Piezo1 activation does indeed lead to changes in the afferent limb of the
micturition reflex. Lastly, though we attempted to study Piezo1 activation in rats with CYPinduced cystitis, the within group variability due to the CYP treatment was too high to
assess any changes related to Piezo1 (data not shown). Additionally, the lack of available
and specific Piezo1 inhibitors makes studying Piezo1 functional contributions to overactive
bladder in rats challenging. Future studies could use conditional floxed Piezo1-knockout
mice under direction of a uroplakin B promotor to knockdown Piezo1 in the urothelium
and determine the effects of local Piezo1 inhibition on pathological bladder function.
Research shows that mRNA and protein expression of Piezo1 increase in the whole
bladder of rats after chronic CYP-induced cystitis (Liu, Sun et al. 2018). Further, a novel
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role for Piezo2 as a mechnosensor has recently been elucidated in urothelial cells
(Marshall, Saade et al. 2020). Given this and previous data implicating TRP channels in
mechanosensation in the bladder (Birder, Nakamura et al. 2002, Gevaert, Vriens et al.
2007), we hypothesized that there would be tissue-specific regulation of MSC mRNA
during varying durations of CYP-induced cystitis in the urothelium vs. the detrusor.
Though we did show MSC upregulation with chronic CYP treatment, we did not see
specific regulation in the urothelium compared to the detrusor; both layers of the bladder
wall showed the same trends in MSC gene regulation with CYP-treatment duration (Fig.
3-2). Though overall expression of MSCs is higher in the urothelium than the detrusor (data
not shown), the similar trend in regulation as a result of CYP-induced cystitis is an
interesting finding.
After determining changes in gene expression, we investigated functional changes
with Piezo1 activation on a molecular level. To accomplish this, we utilized Ca2+ imaging
in urothelial sheets within a network of urothelial cells before and after Piezo1 activation.
To conduct these studies, we made a switch in species from rat to mouse due to difficulties
with isolating the rat urothelial layer from the underlying lamina propria and connective
tissue, in addition to problems loading the Ca2+ fluorescent dye into the rat urothelial sheets.
Previous research using urothelial cell cultures found that activation of Piezo1 in response
to stretch increased [Ca2+]i and was attenuated upon addition of the non-selective MSC
antagonist, GsMTx4 (3-5 µM), and Piezo1 siRNA knockdown (Miyamoto, Mochizuki et
al. 2014). Given this, we originally hypothesized that CYP-treatment would alter Ca2+
activity. Specifically, since we found increased expression of Piezo1 mRNA in the
urothelium with chronic CYP-treatment (Fig. 3-2c), we hypothesized that superfusion of
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Yoda1 (20 µM) would increase the Ca2+ activity for all groups and would be most robust
in the chronic CYP treated group. However, our results indicated an increase in Ca2+
activity only in the acute and intermediate CYP treated groups (Fig. 3-3). Notably, the
chronic CYP-treatment group had variable changes in Ca2+ activity in response to Piezo1
activation, which was reminiscent of the sizeable variation we saw in Piezo1 gene
expression in the chronic CYP treatment group (Fig 3-2). This suggests that there may be
significant individual differences in the expression and function of MSCs in rodents that
are treated with longer durations of CYP. Future studies are needed to observe the effect
of this variability on the function and expression of Piezo1 in the bladder. Additionally,
there are several avenues for future research to examine the effects of Piezo1 activation on
Ca2+-induced Ca2+release and ATP release from the urothelium.
Piezo1 activation-induced increases in Ca2+ activity and the subsequent release of
ATP onto nerve terminals and may be one explanation for the contribution of Piezo1
signaling in bladder overactivity. However, because we saw functional voiding changes
after Yoda1 infusion in vivo but did not see corresponding Ca2+ activity changes in the
urothelial cells from naïve (no CYP) animals, we wanted to investigate other mechanisms
that could increase voiding frequency. One such mechanism may involve downstream
signaling cascades following Piezo1 activation that leads to increases in bladder wall
permeability. In the current study, we show decreases in several tight junction genes
(Cldn1, Cldn8, and ZO-1) after Yoda1 administration compared to vehicle (Fig. 3-4).
These changes are similar to tight junction gene expression changes seen in the bladders of
patients with IC/BPS (Sanchez Freire, Burkhard et al. 2010). To conclude this with
certainty, future research will need to assess tight junction regulation at the protein level.
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Furthermore, Piezo1 signaling has been linked to the downregulation of Cldn1 via
activation of the rho-associated protein kinase (ROCK) signaling pathway in the intestinal
epithelium (Jiang, Song et al. 2021); specific bladder-centric studies using Ussing
chambers could be conducted to further elucidate this connection and determine the cellular
properties of the uroepithelial barrier following Yoda1 administration.
In conclusion, we show both gene expression changes in the urinary bladder and
functional bladder changes upon local pharmacological activation of Piezo1 under normal
and pathological conditions. The current study highlights Piezo1 as a potential target for
treatment for numerous bladder pathologies, like IC/BPS, and offers a basic mechanistic
understanding of how MSCs contribute to bladder function and dysfunction.
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Tables and Figures

Table 3-1. Sequences of forward and reverse primers
for 9 genes of interest and 2 housekeeping genes used
for RT-qPCR experiments.

Abbreviations: TRPV, transient receptor potential
vanilloid; Cldn, Claudin; ZO-1, zona occludens-1
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Fig. 3-1. Intravesical infusion of Yoda1 alters voiding function. The voiding function of
conscious, freely moving, rats was studied for 24 h post saline infusion (baseline) and compared
to voiding function following Yoda1 (0.4mg/kg) or vehicle (5% DMSO in saline) infusion. (A):
In naïve (no CYP) female rats (n=6), activation of Piezo1 with the agonist Yoda1 significantly
increases number of voids at every timepoint studied until 16 h after infusion (P ≤ 0.05). (B):
This increase in number of voids is matched by a significant decrease in the IMI at the same
timepoints (P ≤ 0.01, 0-4 h, 8-12 h, and 12-16 h and P ≤ 0.001 4-8h post infusion) compared to
vehicle infusion (n=7). (C) These changes in voiding frequency after Yoda1 infusion do not
result in any changes in void mass at any timepoint studied compared to vehicle infusion.
Values are means ± SEM. Statistical analyses were performed using mixed model repeated
measures ANOVA on square root (A) or natural log (B and C) transformed data. Fold-change
transformation in B and C was done post-statistical analysis. *P ≤ 0.05; **P ≤ 0.01, ***P ≤
0.001.
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Fig. 3-2. Chronic, but not acute, CYP-induced cystitis leads to increases in MSC gene
expression. RT-qPCR was used to detect MSC mRNA separately in the urothelium and the
detrusor layers of the urinary bladder at several timepoints of CYP treatment. (A-D): In the
urothelium, TRPV1 (n=3-7) and TRPV4 (n=5-7) mRNA were significantly upregulated after
24 h CYP-treatment (P ≤ 0.01 and P ≤ 0.05, respectively) and after chronic CYP-induced
cystitis (P ≤ 0.0001 and P ≤ 0.01, respectively). Piezo1 (n=5-7) and Piezo2 (n=5-6) were both
significantly increased in the urothelium only after chronic CYP-treatment (P ≤ 0.05 and P ≤
0.01, respectively). (E-H): In the detrusor, TRPV1 (n=2-7) was increased after chronic CYPtreatment (P ≤ 0.01), whereas TRPV4 (n=5-7) was increased following both 24 h CYPtreatment (P ≤ 0.05) and chronic CYP-induced cystitis (P ≤ 0.01). Piezo1 (n=5-7) and Piezo2
(n=5-7) mRNA were also both significantly upregulated in the detrusor following chronic CYPinduced cystitis (P ≤ 0.05, and P ≤ 0.001, respectively). Values are means ± SEM. Data were
normalized to a housekeeping gene (L32) and statistical analyses were performed on raw data
using a One-Way ANOVA before fold-change transformation. *P ≤ 0.05; **P ≤ 0.01, ***P ≤
0.001, P ≤ 0.0001.
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Fig. 3-3. Piezo1 activation with Yoda1 increases Ca2+ output in urothelial cells dependent
on duration of CYP-treatment. Cells from sheets of urothelial tissue were imaged before
(baseline) and after incubation with Yoda1 (20µM) or vehicle (0.1% DMSO). (A): Vehicle
treatment did not alter Ca2+ signaling in urothelial cells compared to baseline. (B): Activation
of Piezo1 with Yoda1 in urothelial cells also did not alter Ca2+ activity in naïve (no CYP) mice
(P = 0.06). (C and D): Urothelial cells from mice treated with 4 h and 24 h of CYP-induced
cystitis showed increased Ca2+ output when compared to their own baselines before Piezo1
activation (P ≤ 0.05 for both). (E): Urothelial cells from chronic CYP-treatment showed
variable Ca2+ activity at baseline and no significant change in this activity following Piezo1
activation. Values are means ± SEM. Statistical analyses were performed on using a paired
Student’s t-test. *P ≤ 0.05.
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Fig. 3-4. Activation of Piezo1 results in a decrease in tight junction mRNA expression in
the urothelium. Rats were externally catheterized and intravesically infused with either Yoda1
(0.4 mg/kg) or vehicle (5% DMSO in saline). RT-qPCR was used to detect expression of tight
junction mRNA in the urothelium from these animals to assess urothelial permeability. The
gene expression of several tight junctions analyzed were significantly downregulated after
Yoda1 administration compared to vehicle including, Cldn1 (P ≤ 0.05), Cldn8 (P ≤ 0.01), and
ZO-1 (P ≤ 0.0001). No statistical differences were seen in Cldn2 or Cldn4 mRNA expression
levels compared to vehicle treatment. Values are means ± SEM. Data were normalized to an
average of two housekeeping genes (L32 and 18S) and statistical analyses were performed on
raw data using an unpaired Student’s t-test before fold-change transformation. *P ≤ 0.05; **P ≤
0.01, P ≤ 0.0001.
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CHAPTER 4: COMPREHENSIVE DISCUSSION AND FUTURE DIRECTIONS
4.1. Dissertation Summary
Bladder function is frequently taken for granted until the emergence of dysfunction.
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is one such cause of pathological
bladder dysfunction that affects up to 6.5% of women and 4.2% of men (Berry, Elliott et
al. 2011, Suskind, Berry et al. 2013). Experts suggest that the economic burden of IC/BPS
in the U.S. is approximately $400 million each year (Anger, Zabihi et al. 2011). Together,
this emphasizes the need for improved diagnosis and treatment options for people with this
pathology. This dissertation seeks to identify possible mediators that perpetuate bladder
overactivity symptoms seen in patients with IC/BPS. We take a neuro-centric approach to
study changes in the afferent limb of the micturition reflex to better understand the
functional differences that occur in bladder function and dysfunction. We identify two
distinct mediators that drive symptoms of bladder overactivity: vascular endothelial growth
factor (VEGF) and its associated receptor, and the mechanosensitive channel, Piezo1.
Using both biochemical and functional assays, we show ways in which each mediator may
contribute to bladder function under normal conditions, as well as bladder dysfunction
upon aberrant activation. This chapter will outline final conclusions, revisit results through
a lens of clinical translatability, and explore future directions for this research.
4.2. Vascular Endothelial Growth Factor (VEGF) Signaling in IC/BPS
Changes in VEGF and VEGF receptor expression throughout the urinary bladder
in animal models of bladder inflammation as well as patients with IC/BPS has been
researched extensively (Cheppudira, Girard et al. 2008, Saban, Backer et al. 2008, Saban,

133

Saban et al. 2008, Saban, Davis et al. 2011, Malykhina, Lei et al. 2012, Dagher, Curatolo
et al. 2017, Furuta, Suzuki et al. 2019). For the first time, results in this dissertation show
that functional blockade of VEGFR2 with Ki8751 improves functional bladder capacity as
evidenced by an increase in infused volume and intermicturition interval in male and
female rats following both acute and chronic cyclophosphamide (CYP)-induced cystitis.
Interestingly, the results show that naïve animals that were not treated with CYP also show
similar changes in bladder function, which suggests a role for VEGF/VEGFR2 signaling
in the normal micturition reflex.
Because we used an intravesical infusion drug delivery method, we most likely
blocked VEGR2 receptors on urothelial cells since they are most proximal to the lumen.
However, because CYP treatment is known to decrease tight junction protein expression
and increase bladder wall permeability, inhibition of VEGFR2 on nerve terminals and even
within the detrusor smooth muscle, cannot be discounted. Though Saban, et al. showed the
highest expression of VEGFR2 in the urothelium (Saban, Backer et al. 2008), future studies
could be done to determine the contributions of blocking VEGFR2 specifically in urothelial
cells using uroplakin-2 driven genetic knockouts in mice.
We did not assess downstream signaling changes upon blockade of VEGFR2, and
to date, no one has looked at the specific changes in cell signaling in VEGFR2
activation/inhibition in urothelial cells. However, in other cell types, activation of VEGFR2
leads to autophosphorylation of the receptor and activation of two distinct cellular
pathways. Like many other receptor tyrosine kinases, VEGF binding to VEGFR2 can result
in the activation of Phospholipase C, gamma 1 (PLCγ1) which can lead to increases in
intracellular Ca2+ concentration and the release of ATP and other signaling molecules from
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urothelial cells (Cunningham, Arrate et al. 1997, Ortéga, Hutchings et al. 1999). In
addition, after activation, VEGFR2 associates with Shc, Grb2 and Nck which leads to the
stimulation of Raf and the eventual activation of the MAPK cascade (D'Angelo, Struman
et al. 1995, D'Angelo, Lee et al. 1997, Kroll and Waltenberger 1997, Ortéga, Hutchings et
al. 1999). This is especially interesting because MAPK pathway activation has been
implicated in pathological bladder signaling. For instance, our lab has previously shown
that inhibition of other components of the MAPK pathways, like MEK, JNK, p38, and
ERK1/2, improve bladder functional outcomes in rodents following CYP-induced cystitis
(Corrow and Vizzard 2007, Corrow and Vizzard 2009, Dugan, Malley et al. 2014). Future
studies could work to assess a link between VEGF/VEGFR2 signaling and these
downstream signaling cascades to determine a specific mechanism as well as identify other
potential targets for clinical intervention.
4.3. VEGF Alternative Splicing in CYP-Induced Cystitis
A hallmark symptom of patients with IC/BPS is chronic pain, typically presenting
as hyperalgesia and/or allodynia due to neurogenic inflammation. Previous research using
a partial saphenous nerve ligation injury (PSNI) to model chronic neuropathic pain showed
differential regulation of VEGF alternative spice variant expression (VEGFxxxa vs.
VEGFxxxb; Hulse, Drake et al. 2016). Prior to this dissertation, VEGF alternative splice
isoform expression had not been characterized in the lower urinary tract (LUT) or
associated nervous system tissues. By quantifying gene expression, our data show that the
proportion of total VEGF that is expressed as the VEGF-Axxxa and the VEGF-Axxxb
isoform is LUT tissue specific. Further, the results show that CYP-induced cystitis leads to
an increase in the expression of the VEGFxxxa isoform, but contrary to the literature in other
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pain models, our data show an increase in the expression of the VEGFxxxb isoform.
Notably, these changes were tissue specific such that VEGFxxxa and VEGFxxxb expression
increased in the urothelium after acute CYP treatment, while increases in expression were
not seen until the chronic CYP treatment timepoint in the lumbosacral DRG and spinal
cord. Differences in our findings compared to the literature may be due to the quantification
of mRNA vs. protein and may suggest a role for posttranslational modification of
VEGFxxxb. Alternatively, since this is the first time VEGF isoforms have been studied in
the LUT, we may be observing tissue specific alterations in the presence of VEGFxxxa and
VEGFxxxb splice variants.
In our functional studies, the inhibition of VEGFR2 blocked both isoforms from
signaling with the receptor. Though we did not conduct a mechanical hypersensitivity assay
to assess pain related changes with VEGFR2 inhibition, since we blocked both pro- and
anti-nociceptive signaling (i.e.: we blocked both VEGFxxxa and VEGFxxxb from binding to
the receptor), we may not have seen changes in pain related behaviors. However, because
VEGFxxxb signaling is anti-nociceptive, biasing its expression to promote its specific
binding to the receptor may decrease pain behaviors. To accomplish this, future
experiments using the CYP model could exogenously introduce VEGFxxxb into the system
to encourage competitive binding to VEGFR2. In support of this, central administration of
rhVEGF165b reduced both mechanical and thermal hyperalgesia in a model of PSNI (Hulse,
Beazley-Long et al. 2014).
Another way to bias the production of VEGFxxxb over VEGFxxxa would be to target
the enzyme, serine-arginine rich protein kinase 1 (SRPK1). This kinase phosphorylates
serine-arginine rich splice factor 1 (SRSF1) which controls VEGF splicing and is
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preferential to the production of the proximal splice product, VEGFxxxa (Nowak, Woolard
et al. 2008, Nowak, Amin et al. 2010, Amin, Oltean et al. 2011). Though CYP-induced
cystitis and PSNI both result in neuropathic pain, future studies would need to determine
if either treatment would be effective, since our studies using the CYP model did not show
the same changes in expression of the isoforms. Still, the data included in this dissertation
provide information about VEGF alternative splice variant expression in a different context
of neuropathic pain.
4.4. Mechanotransduction in Urinary Bladder Function and Dysfunction
Mechanosensitive channels (MSCs) play an essential role in mechanotransduction
in the urinary bladder, and Piezo1 is a recent addition to the family of MSCs that have been
identified in the LUT. The results in this dissertation show that local, pharmacological
Piezo1 activation leads to functional voiding changes in vivo as evidenced by increased
voiding frequency, when using a non-invasive, natural voiding assay. We then show
upregulation of Piezo1 and other MSC genes with chronic CYP-induced cystitis, but not
acute nor intermediate treatments in both the urothelium and detrusor. We sought to
correlate expression changes with functional molecular changes, however, when using
Ca2+ imaging to determine Ca2+ activity in these same CYP treatment groups (acute,
intermediate, and chronic), we found that following Piezo1 activation with Yoda1, Ca2+
output only increased in the acute, and intermediate CYP treatment timepoints, not in the
control (no CYP) nor chronic CYP treatment timepoint.
Though these results suggest fundamental differences in gene expression and
functional Piezo1 activation and Ca2+ activity, they also provide evidence for a connection
between Piezo1 activation and functional bladder changes. However, there are still gaps in
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our understanding of this mechanism. For instance, we did not examine the direct cellular
effects of this increase in Ca2+ output. Previous research in TRP channels shows that their
activation and subsequent intracellular [Ca2+] increase leads to ATP release from urothelial
cells that causes functional voiding changes (Birder, Nakamura et al. 2002, Birder,
Kullmann et al. 2007, Girard, Campbell et al. 2019). Though there are many similarities
between TRP channels and the Piezo1 channel in mechanotransduction, the effect of
Piezo1 activation on ATP release still requires investigation in urothelial cells. Currently,
the specific mechanism for distension-induced ATP release is unclear, however, an
increase in intracellular [Ca2+] resulting in the release of Ca2+ from intracellular stores
seems to play a role (Matsumoto-Miyai, Kagase et al. 2011, Dunning-Davies, Fry et al.
2013). Regardless of the precise mechanism of Ca2+-induced ATP release, excessive ATP
release from urothelial cells has been shown to be a driver of bladder overactivity in
patients with IC/BPS (Sun, Keay et al. 2001, Birder, Barrick et al. 2003). Future research
could approach this by using an ATP luminescence assay to quantify ATP release from the
urothelium upon Piezo1 activation.
Lastly, the contribution of Piezo1 activation to changes in bladder function is most
likely multifaceted in that Piezo1 activation may be contributing to several signaling
cascades that drive bladder overactivity. To this end, recent research in the intestinal
epithelium suggests that Piezo1 activation is associated with downregulation of tight
junction proteins, like Claudin1 (Cldn1), via negative regulation of ROCK1/2 activity
(Jiang, Song et al. 2021). Because of this as well as evidence that suggests a connection
between urothelial stretch and tight junction protein organization, we quantified the
expression of several tight junction genes using RT-qPCR and show that Cldn1, Cldn8,
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and zona occludens-1 (ZO-1) are downregulated in bladders that had previously been
treated with intravesical administration of Yoda1. This result is particularly interesting
given the known downregulation of tight junctions in bladders of patients with IC/BPS
(Sanchez Freire, Burkhard et al. 2010). Future research could examine Piezo1 activity and
phospho-ROCK1/2 in CYP-induced cystitis to determine if a similar mechanism in
urothelial cells leads to bladder wall permeability.
4.5 Final Conclusions and Clinical Implications
The results from this dissertation highlight two potential mediators that drive the
complex pathophysiology of IC/BPS: VEGF/VEGFR2 signaling and Piezo1 activation.
Though seemingly unrelated, both VEGFR2 and Piezo1 activation contribute to increased
bladder voiding activity, a hallmark symptom of patients with IC/BPS. Even with
symptoms of severe bladder urgency and voiding frequency, diagnosing IC/BPS is
challenging and can take several years after the first onset of symptoms. Because of this
and the lack of known etiology, research into the mechanisms that perpetuate and
contribute to these symptoms is crucial to improving clinical outcomes for these patients.
There are several known mediators that contribute to the underlying neurocircuitry
of micturition and the pathophysiology of IC/BPS. Indeed, there are many convergent and
as well as distinct signaling mechanisms that add to the inflammatory environment and
neural plasticity in bladders of patients with IC/BPS. For example, submucosal
angiogenesis is a known pathogenic feature of IC/BPS. Research into understanding
VEGF/VEGFR2 signaling provides insight into this feature and works to identify potential
overlap with other mediators of IC/BPS. Similarly, a compromised urothelial barrier is
another pathogenic feature of patients with IC/BPS. Examining the effect of Piezo1
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signaling on tight junction gene expression may help in solving that piece of the
pathogenesis puzzle. It is impossible to understand the pathophysiology of IC/BPS without
understanding the breadth of neurochemical and other modulators that play a role in
facilitating the symptoms of bladder pain, urgency, and frequency.
Future research must consider a variety of animal models as well as differing
presentations of clinical IC/BPS to identify these overlaps in cell signaling and specific
contribution to the pathophysiology (e.g.: increase in inflammatory cell infiltration,
increase in bladder wall permeability, increase in C-fiber plasticity, etc.). This type of
understanding will ultimately provide a variety of treatment targets for patients with this
disorder. Specifically, by characterizing the different mechanisms at play, clinical
treatment options will be able to be individualized depending on the distinct needs of the
patient.
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APPENDIX I
The following data within Appendix I represent unpublished data that coincide
with Chapter 3 of this dissertation.
GsMTx4 does not attenuate CYP-induced voiding dysfunction in acute nor chronic
CYP treatment
Previous research using unconscious urodynamic measurements shows that
administration of GsMTx4 (2.5µM) improves voiding function in rats treated with chronic
CYP, as demonstrated by an increase in intermicturition interval (IMI) and a decrease in
maximum bladder pressure (Liu, Sun et al. 2018). Because we showed an increase in
voiding frequency following Piezo1 activation with Yoda1 in conscious, freely moving
rats using the Urovoid system in Chapter 3 of this dissertation, we wanted to see if
antagonism of Piezo1 with GsMTx4 would lead to a decrease in voiding frequency in both
acute and chronic CYP treatment.
In both acute (Fig. I-1A) and chronic (Fig. I-1B) CYP treatment, we did not see a
difference in voiding frequency with infusion of GsMTx4 (5µM) compared to vehicle
infusion (10% sterile water in saline). In both CYP treatment durations (acute and chronic),
we observed substantial within-group variability in the number of voids per time bin which
made analyzing the contribution of Piezo1 to voiding dysfunction challenging.
CYP treatment leads to minimal MSC gene expression regulation in lumbosacral
dorsal root ganglia (DRG)
In Chapter 3 of this dissertation, we found increases in MSC (TRPV1, TRPV4,
Piezo1, and Piezo2) gene expression. In the urothelium and detrusor from rats treated
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chronically but not acutely with CYP. Given the link between neurogenic inflammation
and associated neuroplasticity that results in gene transcript changes, we wanted to observe
any changes in gene expression in the lumbosacral DRGs of the MSCs we previously
examined.
In the L6 DRG (Fig I-2A-D), we found that TRPV1 and TRPV4 transcripts are both
upregulated (P ≤ 0.01) after 24 h of CYP treatment compared to control (no CYP). We did
not observe regulation of Piezo1/2 transcripts, nor did we observe regulation at any other
CYP treatment timepoints for TRPV1/4. In the S1 DRG (Fig. I-2E-H), we found that
TRPV1 mRNA expression decreased after 4 h of CYP treatment (P ≤ 0.05) and after
chronic CYP treatment (P ≤ 0.01) compared to control. Like the L6 DRG, we did not
observe further changes in MSC gene regulation in the S1 DRG.
Piezo1 activation with Yoda1 downregulates gap junction and inflammatory
mediator gene expression in the urothelium
When the bladder fills and becomes distended, Piezo1 and other MSCs on urothelial
cells become activated. This can facilitate the release of ATP from the urothelium onto
nerve terminals located in the bladder wall. This ATP can be released in vesicles, or it can
be transported out of the cell by gap junctions like connexin-43 (Cx43) and pannexin-1
(Panx1; Locovei, Wang et al. 2006, Sengiku, Ueda et al. 2018, Kono, Ueda et al. 2021).
These gap junctions are upregulated in multiple bladder pathologies (Haefliger, Tissières
et al. 2002, Christ, Day et al. 2003). In addition, inflammatory markers including CCL2
and IL-6 are upregulated in patients with IC/BPS and following Piezo1 activation (Blythe,
Muraki et al. 2019). Contrary to the literature and our original hypothesis, activation of
Piezo1 delivered via external catheterization and infusion of Yoda1 leads to a
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downregulation of both Cx43 and Panx1 (P ≤ 0.01 for both), as well as CCL2 (P ≤ 0.05;
Fig. I-3). We did not observe changes in IL-6 regulation after Yoda1 infusion.
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Fig. I-1. Intravesical infusion of GsMTx4 does not significantly alter CYP-induced voiding
dysfunction. The voiding function of conscious, freely moving, rats was studied for 24 h post
saline infusion (baseline) and compared to voiding function following acute or chronic CYP
and treatment with GsMTx4 (5uM) or vehicle (10% sterile water in saline) infusion. (A): Rats
treated with an acute dose of CYP and infused with GsMTx4 (n=10) did not show changes in
number of voids compared to rats infused with vehicle (n=6). (B): Rats treated with a chronic
dose of CYP and infused with GsMTx4 (n=4) did not show changes in number of voids
compared to rats infused with vehicle (n=6) at any timepoint tested. Values are means ± SEM.
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Fig. I-2. MSC gene expression in lumbosacral DRGs with varying durations of CYP
treatment. RT-qPCR was used to detect MSC mRNA in the L6 and S1 DRGs at several
timepoints of CYP treatment. (A-D): In the L6 DRG, TRPV1 (n=6-7) and TRPV4 (n=5-7)
increased significantly (P ≤ 0.01 for both) after 24 h treatment of CYP compared to control (no
CYP). There was no statistical change in Piezo1 (n=6-7) or Piezo2 (n=6-7) transcript at any
CYP treatment timepoint. (E-H): In the S1 DRG, TRPV1 (n=5-7) mRNA expression decreased
at the 4 h CYP treatment timepoint (P ≤ 0.05), and the chronic CYP treatment timepoint (P ≤
0.01) compared to control. TRPV4 (n=5-7), Piezo1 (n=5-7), and Piezo2 (n=6-7) gene
expression were unchanged in all CYP treatment timepoints. Values are means ± SEM. Data
were normalized to a housekeeping gene (18S) and statistical analyses were performed on raw
data using a One-Way ANOVA before fold-change transformation. *P ≤ 0.05; **P ≤ 0.01.
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Fig. I-3. Activation of Piezo1 results in a decrease in gap junction and inflammatory
mediator expression in the urothelium. Rats were externally catheterized and intravesically
infused with either Yoda1 (0.4 mg/kg) or vehicle (5% DMSO in saline). RT-qPCR was used to
detect expression of gap junction (Cx43 and Panx1) and inflammatory mediator (IL-6 and
CCL2) mRNA in the urothelium. (A): Cx43 (n=6-9) and Panx1 (n=6-9) transcripts were both
downregulated following Yoda1 infusion in naïve (no CYP) rats compared to vehicle (P ≤ 0.01
for both). (B): CCL2 (n=6-8), but not IL-6 (n=4-7), was downregulated following Yoda1
infusion compared to vehicle (P ≤ 0.05). Values are means ± SEM. Data were normalized to an
average of two housekeeping genes (L32 and 18S) and statistical analyses were performed on
raw data using an unpaired Student’s t-test before fold-change transformation. *P ≤ 0.05; **P ≤
0.01.

References
Blythe, N. M., K. Muraki, M. J. Ludlow, V. Stylianidis, H. T. J. Gilbert, E. L. Evans, K.
Cuthbertson, R. Foster, J. Swift, J. Li, M. J. Drinkhill, F. A. van Nieuwenhoven, K.
E. Porter, D. J. Beech and N. A. Turner (2019). "Mechanically activated Piezo1
channels of cardiac fibroblasts stimulate p38 mitogen-activated protein kinase
activity and interleukin-6 secretion." The Journal of biological chemistry 294(46):
17395-17408.
Christ, G. J., N. S. Day, M. Day, W. Zhao, K. Persson, R. K. Pandita and K. E. Andersson
(2003). "Increased connexin43-mediated intercellular communication in a rat
model of bladder overactivity in vivo." Am J Physiol Regul Integr Comp Physiol
284(5): R1241-1248.
Haefliger, J. A., P. Tissières, T. Tawadros, A. Formenton, J. L. Bény, P. Nicod, P. Frey
and P. Meda (2002). "Connexins 43 and 26 are differentially increased after rat
bladder outlet obstruction." Exp Cell Res 274(2): 216-225.
Kono, J., M. Ueda, A. Sengiku, S. O. Suadicani, O. Ogawa and H. Negoro (2021).
"Urothelium-Specific Deletion of Connexin43 in the Mouse Urinary Bladder Alters
Distension-Induced ATP Release and Voiding Behavior." Int J Mol Sci 22(4).
175

Liu, Q., B. Sun, J. Zhao, Q. Wang, F. An, X. Hu, Z. Yang, J. Xu, M. Tan and L. Li (2018).
"Increased Piezo1 channel activity in interstitial Cajal-like cells induces bladder
hyperactivity by functionally interacting with NCX1 in rats with
cyclophosphamide-induced cystitis." Experimental & molecular medicine 50(5):
60-60.
Locovei, S., J. Wang and G. Dahl (2006). "Activation of pannexin 1 channels by ATP
through P2Y receptors and by cytoplasmic calcium." FEBS Lett 580(1): 239-244.
Sengiku, A., M. Ueda, J. Kono, T. Sano, N. Nishikawa, S. Kunisue, K. Tsujihana, L. S.
Liou, A. Kanematsu, S. Shimba, M. Doi, H. Okamura, O. Ogawa and H. Negoro
(2018). "Circadian coordination of ATP release in the urothelium via connexin43
hemichannels." Sci Rep 8(1): 1996.

176

